The rising cases of respiratory disorders and growing adoption of generic inhalers are among the key forces bolstering the market. However, high lack of early diagnosis and high cost of inhalers hinders the respiratory inhalers market growth.

New York, March 21, 2023 (GLOBE NEWSWIRE) -- announces the release of the report "Respiratory Inhalers Market Forecast to 2028 - COVID-19 Impact and Global Analysis By Product Type [Nebulizers, Metered Dose Inhalers, and Dry Powder Inhalers], Technology, and Disease Indication" -

Inhalers for respiratory diseases like chronic obstructive pulmonary disease (COPD) and asthma are medical devices which deliver medicine to prevent, control and treat symptoms and help reduce exacerbations. The medicine inside the inhaler goes directly into the airways when the patient breathe in.

The prevalence of asthma, chronic obstructive pulmonary disease (COPD), cystic fibrosis, and other respiratory diseases is increasing across the globe.For example, according to the World Health Organization (WHO), in 2022, the number of asthma-related deaths in 2019 was 455,000.

In addition, the Burden of Disease Study in 2019 recorded 212.3 million cases of COPD worldwide, resulting in 3.3 million deaths. According to the March of Dimes Organization, there were between 70,000 and 100,000 cases of cystic fibrosis across the globe in 2019. In addition, one of the major causes of respiratory diseases such as COPD and asthma is the rise in air pollution. The Organization for Economic Co-operation and Development (OECD) estimates that global emissions of greenhouse gases are likely to increase by ~50% by 2050, mainly due to a 70% increase in CO2 emissions. In addition, it is estimated that the atmospheric concentration of greenhouse gases could reach 685 parts per million (ppm) CO2 equivalent by 2050, which would cause average temperatures to rise 3–6ºC above pre-industrial levels. In addition, the beneficial effects on patients through combination therapy for asthma have increased, which has increased the demand for respiratory inhalers market such as dry powder inhalers and soft-mist inhalers, as they are one of the best ways to administer combination drugs. Hence, the increasing prevalence of respiratory diseases among the growing population is one of the factors driving the respiratory inhalers market growth.

Product Type Insights

The respiratory inhalers market, by product type, is segmented into nebulizers, metered dose inhalers, and dry powder inhalers. The dry powder segment held the largest market share in 2021, however metered dose inhalers is anticipated to register the highest CAGR of 6.3% during the forecast period (2022–2028). Metered dose inhalers (MDIs) are handheld pressurized inhalation systems that deliver small, precisely measured therapeutic doses of medication directly to the airways of a patient. They are handheld pressurized inhalation systems that deliver small, precisely measured therapeutic doses of medication directly to the airways of a patient. MDI devices include a valve and actuator designed to facilitate a consistent delivery of a specific dose of a drug to the patient in particles of a specific size distribution delivered via a propellant. MDIs require gas propellants with vapor pressures that allow them to be liquefied at ambient temperatures at pressures between 40 and 70 psi inside the canister. Propellants used in MDIs for inhaled medications must be certified by the FDA as current Good Manufacturing Practice (cGMP) inhalation grade with high purity levels. Propellants for MDIs must meet cGMP requirements for the methods, facilities, and controls used in manufacturing, processing, and packaging to ensure the product is safe for use and that it has the ingredients and strength it claims to have (FDA 2020a). The first HFC MDI approved by the FDA was for albuterol sulfate utilizing HFC-134a propellant in 1996. As of 2020, the number of FDA-approved MDI products has reached 13 and is expected to expand considerably.

The metered dose inhalers are further classified into pressured metered dose inhalers and connected metered dose inhalers.The pressured metered dose inhaler (pMDI) has been a mainstay in the treatment of respiratory diseases, especially asthma since its introduction in 1956.

It is the most commonly prescribed delivery system for administering inhaled bronchodilators and antiinflammatory agents worldwide.Spacer devices, when used properly, substantially improve the delivery of pMDI-generated aerosols to the distal airways.

The pMDI, used alone or in combination with a spacer or valved-holding chamber, is the most convenient and cost-effective way to administer aerosolized medications for most patients.A pMDI contains drug, which usually is either crystallized or in solution, along with the propellant and a surfactant.

Connected metered dose inhalers is a type of MDI in which a device is connected to the manual inhaler so that it becomes a digitally operated MDI. For instance, Aptar Pharma has launched HeroTracker Sense, a digital respiratory health solution that turns a standard metered dose inhaler (pMDI) into a smart connected healthcare device. HeroTracker Sense is a metered-dose inhaler (MDI) add-on connected device, designed to address patient inhalation technique and adherence. By attaching to the canister of an MDI, HeroTracker Sense has several features to help asthma and COPD patients take their medication in a more informed way. The sensors in the device enable the creation and supply of information such as co-ordination of inspiration with actuation, flow rate and inhalation duration.

Technology Insights

Based on technology, the respiratory inhalers market is divided into manually operated inhalers and digitally operated inhalers. The manually operated inhalers segment held the largest market share in 2021 and it is expected to grow at the highest CAGR of 6.0% during the forecast period. Manually operated inhalers deliver short bursts of medicine quickly and easily via a portable and handheld device. The user simply removes the cap, shakes the inhaler for approximately 5 seconds, places the mouthpiece of the inhaler in their mouth, and presses the pump to release the missed dose of medication while breathing in slowly and deeply. Manual inhalers require some practice to administer medicine properly, which may be difficult for small children or elderly patients with respiratory illnesses.
Read the full report:

About Reportlinker
ReportLinker is an award-winning market research solution. Reportlinker finds and organizes the latest industry data so you get all the market research you need - instantly, in one place.


CONTACT: Clare: [email protected] US: (339)-368-6001 Intl: +1 339-368-6001

Source link

Rockville, March 21, 2023 (GLOBE NEWSWIRE) -- The market for digital respiratory devices, which had a market value of US$ 43 billion in 2022, is anticipated to grow at a CAGR of 25% from that year through 2032. Improvements in the manufacture of breathing apparatus have been driven by the rise in respiratory illnesses.

Patients with asthma and chronic obstructive pulmonary disease (COPD) have increased use of digital respiratory devices as they have demanded greater accuracy in medication administration. Government reimbursement policies that support the manufacturing and distribution of digital respiratory devices.

Download Free Sample Copy of This Report –

The Digital Respiratory Devices market has several drivers, including:

  • The rising prevalence of respiratory diseases, such as asthma, chronic obstructive pulmonary disease (COPD), and cystic fibrosis, is a major driver of the digital respiratory devices market. These devices help patients manage their conditions by monitoring symptoms, tracking medication usage, and providing personalized feedback to improve outcomes.
  • Advances in technology, such as the Internet of Things (IoT), artificial intelligence (AI), and machine learning (ML), have made it possible to develop more sophisticated and accurate digital respiratory devices.
  • Digital respiratory devices are a cost-effective solution for patients and healthcare providers, reducing hospitalization and emergency room visits. They also provide a more convenient and comfortable option for patients to manage their respiratory conditions.
  • Governments are taking initiatives to promote digital health technologies, including digital respiratory devices, to improve healthcare outcomes and reduce healthcare costs. For example, in the US, the Centers for Medicare and Medicaid Services (CMS) has approved reimbursement for certain digital respiratory devices, increasing adoption rates among patients and providers.

Key Market Trends:

  • Wearable devices, such as smart inhalers and respiratory monitors, are a growing trend in the digital respiratory devices market. These devices can track patient symptoms and medication usage, providing personalized feedback and insights to improve disease management.
  • The COVID-19 pandemic has accelerated the trend toward telemedicine, including virtual consultations and remote patient monitoring. Digital respiratory devices can be integrated into telemedicine platforms, allowing healthcare providers to monitor patients remotely and provide real-time feedback and support.
  • Personalized medicine is a growing trend in healthcare, and digital respiratory devices are no exception. These devices can collect and analyze patient data to provide personalized feedback and treatment plans, improving patient outcomes and reducing healthcare costs.
  • Artificial intelligence (AI) and machine learning (ML) are increasingly being used in the development of digital respiratory devices. These technologies can analyze large amounts of patient data to identify patterns and provide insights into disease management, improving patient outcomes.
  • Home-based care is a growing trend in healthcare, driven by the desire to reduce hospitalization and healthcare costs. Digital respiratory devices can be used in home-based care settings, providing patients with a convenient and comfortable option for disease management while reducing healthcare utilization.

Get Customization on this Report for Specific Research Solutions –

Limited awareness about digital respiratory devices among patients and healthcare providers can be a significant restraint for the market. Many patients and healthcare providers may not be aware of the benefits and potential applications of these devices, limiting their adoption.

  • The high cost of digital respiratory devices can be a significant restraint for patients, especially those in low- and middle-income countries. Many patients may not be able to afford these devices, limiting their accessibility and adoption.
  • Data privacy and security concerns can also be a restraint for the digital respiratory devices market. As these devices collect and transmit sensitive health data, patients and healthcare providers may be hesitant to use them due to concerns about data privacy and security breaches.

Competitive Intelligence:
Various key players in the market are focusing on strategies such as acquisitions and mergers to establish a sustainable market share.

  • For instance, Digital therapeutics are software-based interventions designed to treat behavioral health disorders. These include mobile apps, online programs, and virtual reality experiences. Moreover, several new digital therapeutics have recently been launched, including Pear Therapeutics' ReSET-O for opioid use disorder and Woebot Health's chatbot therapy for depression and anxiety.
  • Moreover, TMS devices have recently been launched, including MagVenture's MagVita TMS Therapy system. Transcranial Magnetic Stimulation (TMS): TMS is a non-invasive brain stimulation technique that has been approved by the FDA for the treatment of depression system.

Key Companies Profiled

  • COHERO Health Inc.
  • Cognita Labs
  • Adherium limited
  • Amiko Digital Health Limited
  • Teva pharmaceuticals industries Ltd.
  • Propeller Health
  • Novartis AG
  • Pneuma Respiratory Inc.
  • 3m Health Care Limited
  • AireHealth, Inc.

Key Segments in Digital Respiratory Devices Industry Research

  • By Product:
    • Smart Inhalers & Nebulizers
    • Sensors & Apps
  • By Indication:
  • By Distribution Channel:
    • Hospital Pharmacies
    • Retail Pharmacies
    • Online Pharmacies
  • By End Use:
    • Hospitals
    • Homecare Settings
    • Other settings
  • By Region:
    • North America
    • Europe
    • East Asia
    • South Asia
    • Oceania
    • Latin America
    • Middle East & Africa

Quick Buy (Special Offer Save 20% Now): Digital Respiratory Devices Market

Key Questions Covered in the Digital Respiratory Devices Market Report

  • What will be the estimated size of the Market in 2023?
  • At what rate will the global Digital Respiratory Devices sales grow until 2033?
  • Which are the factors hampering the Digital Respiratory Devices demand?
  • Which region will spearhead the growth in the global industry during 2023-2033?
  • Which are the factors driving sales in the Digital Respiratory Devices Market during the forecast period?

Check out more related studies published by Fact.MR Research: 
Speech Generating Devices Market Size: The global speech generating devices market size reached a valuation of around US$ 205 Mn in 2020, and is slated to accelerate at a CAGR of 10% through 2031. Demand for text-to-speech devices is high and set to remain so, increasing at a CAGR of 9%.

Phototherapy Devices Market Sales: Sales of phototherapy devices are slated to surge at a CAGR of 7% to top US$ 1.5 Bn by 2031. Demand for LED-based phototherapy devices is set to increase at a CAGR of 6% across the assessment period of 2021 to 2031.

Radiotherapy Devices Market Demand: Radiotherapy equipment demand slated to accelerate at a CAGR of 7% to top US$ 10 Bn by 2031. Demand for linear accelerator devices, which holds the highest market share, is set to increase at a CAGR of 6% across the assessment period of 2021 to 2031.

Dermatology Devices Market Growth: Revenue from the global dermatology devices market reached US$ 12 Billion in 2020, and the market is predicted to reach US$ 39 Billion by 2031. As per the study, the dermatology devices market growth is anticipated to surge at an impressive CAGR of around 12.5% over the next ten years.

About Fact.MR
We are a trusted research partner of 80% of fortune 1000 companies across the globe. We are consistently growing in the field of market research with more than 1000 reports published every year. The dedicated team of 400-plus analysts and consultants is committed to achieving the utmost level of our client’s satisfaction.

US Sales Office
11140 Rockville Pike
Suite 400
Rockville, MD 20852
United States
Tel: +1 (628) 251-1583, +353-1-4434-232 (D)
Connect to Author: Mr. Shambhu Nath Jha
Email : [email protected]
Sales Team : [email protected]
Follow Us: LinkedIn | Twitter | YouTube

Source link

Overactive T2 inflammation, a type of immune response linked to asthma, may be associated with worse symptoms of cystic fibrosis (CF), a finding that could pave the way for using anti-asthmatics for CF, a study suggests.

The study, “Association between Cystic Fibrosis exacerbations, lung function, T2 inflammation and microbiological colonization,” was published in Allergy, Asthma & Clinical Immunology.

T2 inflammation refers to a type of immune response involving white blood cells called eosinophils. When the body encounters a trigger such as pollen or dust, eosinophils are activated and release certain chemicals that cause inflammation.

While this is part of a normal immune response, T2 inflammation can sometimes go into overdrive. When this happens, it can cause asthma or other breathing problems.

More than a third of people with CF in the CF Foundation Patient Registry report having asthma. While CF and asthma have different causes and mechanisms, they can both lead to similar symptoms such as wheezing (noisy breathing with a whistling sound), coughing, and difficulty breathing.

There’s some evidence that T2 inflammation can contribute to a worsening of symptoms in people with CF. For example, when the lungs get inflamed, breathing can become harder and a flare-up of symptoms, called a pulmonary exacerbation, can occur.

Recommended Reading

An illustration of a child coughing.

T2 inflammation markers and CF

Researchers in the U.S. hypothesized that if someone with CF has more T2 inflammation markers, their lungs might not work as well and they may have more exacerbations and be more likely to get an infection.

To test this, they looked at the clinical data of 74 adults who received care at the University of Virginia Medical Center from 2013 through 2018.

The patients’ mean age was 35.1 and 40 were women. More than two-thirds were receiving inhaled corticosteroids or CFTR modulators, a type of medication designed to tackle the underlying defect in CF.

The most common diseases coexisting with CF were asthma (82.3%), followed by CF-related diabetes (43.2%), and allergic bronchopulmonary aspergillosis (8.3%), which results from an infection with the fungus Aspergillus fumigatus in the lungs.

Average absolute eosinophil count (the total number of eosinophils) a year over the study period exceeded 300 cells per microliter of blood in 34 (45.9%) patients. Its median was significantly higher in patients with more than two exacerbations a year than in those with two or fewer.

The odds of more exacerbations happening with a high eosinophil count were 1.88 times the odds of them happening in those with a low eosinophil count. During an exacerbation, a patient may have to be hospitalized or placed on intravenous (into-the-vein) antibiotics.

As the eosinophil count increased, the probability the measurement was taken during an exacerbation also increased. It’s possible that the eosinophil count is “a marker of T2 inflammation regardless of trigger,” the researchers wrote.

While the researchers confirmed their hypothesis that a higher eosinophil count is linked to more frequent exacerbations, “it is unclear if exacerbations cause increased T2 inflammation or T2 inflammation predisposes to increased exacerbations,” they wrote.

The researchers also checked the levels of immunoglobulin E (IgE), an antibody produced by the immune system in response to a trigger. Fourteen (18.9%) patients had a maximum IgE that exceeded 180 international units per milliliter of blood.

Higher IgE levels were linked to a greater number of exacerbations a year, even after adjusting for the presence of atopy, which is a tendency to mount a heightened immune response to common allergens that would otherwise be harmless.

“This is a new finding and suggests that T2 inflammation may be partially responsible for increased exacerbations,” the researchers wrote.

A decline in lung function, measured using the percent predicted forced expiratory volume in one second, was linked to both higher absolute eosinophil count and IgE levels. The relationship held true after adjusting for age, sex, and the presence of a number of species of bacteria or fungi.

These findings support the use of anti-asthmatics in people with CF, which could have “the potential to lower the health care costs of hospitalization and decrease exposure to intravenous antibiotics,” the researchers wrote.

For example, mepolizumab, a GSK medication sold as Nucala and approved for severe asthma associated with eosinophils, has improved the clinical course of three adults with CF who had indicators of T2 inflammation.

Source link

“Go, go, go!” my nurse says while coaching me through my pulmonary function test (PFT). I’m pushing air into a mouthpiece that’s connected to a computer with a robotic arm that moves up and down to adjust for the height of the patient using it. My right hand grasps the plastic arm connecting the two like it’s a handle, and with my left hand, I hold the blue nose clips that keep me from accidentally breathing through my nose.

Similar to other columnists, I’ve previously discussed my ongoing PFT performance anxiety. Often, doctors’ treatment recommendations are based on the outcome of my PFTs. Yet I don’t always feel like they’re reflective of how I feel as a patient.

My mouth is wrapped tightly around the mouthpiece as I try to make a tight seal with my lips, as instructed. I do my best to keep my teeth out of the way. The nurse is pointing to a bar on the screen that’s slowly crawling up the monitor while we wait for it to go from in-progress gray to bright green, which marks some level of success.

Recommended Reading

A hand holds up a coin against a backdrop of dollar signs and packets of money.

“Inhale all the way,” the nurse says while relaxing her body with me. We wait for the line tracking the pressure of my breath to reach its final destination on the x-axis of the graph at the bottom of the screen.

“Hold it a little longer,” she tells me, and I’m a little surprised by the feedback. Having done this test for so many years, I thought I knew what I was doing.

She points to the line that signals the moment I inhaled fully. “See how this goes straight up?”

I nod. It looks how it always looks when I do this test, I think.

“It shouldn’t do that,” she says, pointing to the line that tracks my inhalation, which goes straight as an arrow toward the webcam at the top of the laptop. She clicks around a few times on the computer to open a blank plane.

Try again

I start again by breathing normally and then inhale full and sharp when she tells me to. When I almost feel the need to exhale, she tells me to hold it. Keep going.

Whereas before the line went straight up, this time it draws a small jut to the left before continuing back up in a straight line.

My forced expiratory volume in the first second jumps by over 5%, and I can’t help but wonder if I’ve been doing this test wrong all this time or if I’ve just never noticed the jut that appears like a cliff in the line that’s drawn as I inhale all the way, with so much force it almost hurts.

“Do you see how that improved?” she asks, pointing to the differences in the patterns.

I’m glad to have improved my spirometry numbers. But as I go up the stairs to the main floor and walk out to my car, a printout of my results in hand, I can’t help but wonder how much credence we should give to a test with so much opportunity for error.

If one nurse coaching me can make my test go up enough to make a significant impact on my treatment plan, I wonder how much value we should assign to a single measurement when I undoubtedly exist as so much more than the outcome of how a line is drawn on a computer screen.

Note: Cystic Fibrosis News Today is strictly a news and information website about the disease. It does not provide medical advice, diagnosis, or treatment. This content is not intended to be a substitute for professional medical advice, diagnosis, or treatment. Always seek the advice of your physician or other qualified health provider with any questions you may have regarding a medical condition. Never disregard professional medical advice or delay in seeking it because of something you have read on this website. The opinions expressed in this column are not those of Cystic Fibrosis News Today or its parent company, BioNews, and are intended to spark discussion about issues pertaining to cystic fibrosis.

Source link

Osteoporosis is an independent risk factor for all-cause mortality in hospitalized patients with non-cystic fibrosis bronchiectasis (NCFB), according to a study in BMC Pulmonary Medicine.

Because research indicates that osteoporosis affects lung function and outcomes in patients with chronic obstructive pulmonary disease (COPD), researchers sought to determine the extent to which NCFB outcomes were likewise affected by osteoporosis. The researchers therefore investigated the prognostic effect of osteoporosis in hospitalized patients with NCFB and identified clinical risk factors for osteoporosis in this population.

The observational cohort study was conducted at the pulmonary and critical care department of a hospital in Southeast China from September 2017 to December 2021. Investigators enrolled 179 hospitalized patients with bronchiectasis and respiratory symptoms who had NCFB (mean [SD] age, 64.19 [14.12] years). Among those patients, 38 had osteoporosis (median age, 74 years; 34% male), and 141 were without osteoporosis (median age, 64 years; 58% male).

Of the cohort, 154 patients completed the Chronic Airway Assessment Test (CAT) and St. George Respiratory Questionnaire (SGRQ) evaluation. Patients with osteoporosis had significantly increased CAT scores (22.0 vs 17.0) and SGRQ scores (42 vs 27) compared with those without osteoporosis. The Bronchiectasis Severity Index (BSI) scores and Bronchiectasis Aetiology Comorbidity Index (BACI) scores were significantly higher in patients with vs without osteoporosis (14 vs 11 for BSI and 5 vs 4 for BACI).

Our study indicates that comorbid osteoporosis in hospitalized NCFB patients is an independent risk factor for all-cause mortality. Clinicians should pay attention to bone health in patients with chronic pulmonary disease, including bronchiectasis.

The patients with osteoporosis were likely to be older, female, and have cardiovascular disease (CVD), gastroesophageal reflux disease, anemia, postinfection, and regular inhaled corticosteroid (ICS) treatment. Modified Poisson regression analysis showed that age (relative ratio [RR], 1.03), female sex (RR, 2.77), anemia (RR, 2.22), subsequent infection (RR, 1.78), and regular ICS treatment (RR, 3.05) were independent risk factors associated with osteoporosis in hospitalized patients with NCFB.

After a median follow-up of 32 months, 21 (11.73%) patients died. Multivariate regression analysis showed that the BSI score, comorbid osteoporosis, PAH, CVD, and cerebrovascular disease were independently associated with all-cause mortality. The all-cause mortality rate was significantly higher in patients with NCFB and osteoporosis (28.94%; 11/38) vs without osteoporosis (7.09%; 10/141; hazard ratio [HR] 5.34, 95% CI, 2.26-12.67; P <.001).

After adjustment for BSI and other confounding factors, hospitalized patients with NCFB with osteoporosis vs without osteoporosis had an HR of 4.29 (95% CI, 1.75-10.49).

Limitations include the observational, single-center design and the inclusion of only hospitalized patients in the study population. In addition, the level of 1,25 dihydroxyvitamin D or any other factor that has an association between osteoporosis and NCFB was not assessed.

“Age, female sex, history of infection, anemia, and regular ICS treatment were risk factors associated with osteoporosis in hospitalized NCFB patients from Asia,” concluded the investigators. “Our study indicates that comorbid osteoporosis in hospitalized NCFB patients is an independent risk factor for all-cause mortality. Clinicians should pay attention to bone health in patients with chronic pulmonary disease, including bronchiectasis.”

Source link

Cystic fibrosis — a progressive, genetic disease that affects the lungs, pancreas, and other organs — will no longer automatically qualify for a wish from the Make-A-Wish Foundation starting in January 2024. 

The nonprofit foundation, which grants wishes to children with critical illnesses, made the decision because there have been so many major improvements in treatments for the condition. In the past, children with cystic fibrosis often did not survive past their teens or 20s, but many are now living much longer. 

Children with the disease will still be considered for the opportunity to become a princess, virtually travel through space with a real astronaut, or even receive a chicken coop mansion for their beloved birds, but they will be considered on a case-by-case basis, the foundation announced last week. 

A similar change was made for people younger than 18 living with HIV/AIDS. 

Kids with cystic fibrosis will be eligible for a wish if their condition is “accompanied by additional complications or factors that make the current situation critical,” which is in line with the foundation’s mission of serving children with any progressive, degenerative, or malignant condition that puts their lives in jeopardy. 

“This decision was not made lightly, and we understand it may result in some frustration and disappointment,” the Make-A-Wish Foundation said in an update on its website. “As with all wish referrals, we will carefully consider any CF request that a family member, legal guardian, medical professional, or potential wish child believes meets our guidelines.”

Dr. Bruce Marshall, chief medical officer of the Cystic Fibrosis Foundation, told BuzzFeed News that Make-A-Wish worked with CFF to appropriately update its criteria “so it reflects the nuances of living with cystic fibrosis, and to be sure that meaningful decisions are made based on the individual living with the disease and not the disease itself.”

Overall, Marshall said he’s thrilled about what this change ultimately means for the nearly 40,000 children and adults living with cystic fibrosis in the US. 

Cystic fibrosis is an incredibly individualized disease, and not everyone living with CF benefits from the transformative treatments that currently exist,” Marshall said. “The decision made by the Make-a-Wish Foundation to update its criteria is a reflection of the tremendous story that is cystic fibrosis.”

Because of improved medical treatments and care, people born with cystic fibrosis today are expected to live 15 years longer than those born a decade ago, with more than half expected to live 53 years compared with 38 previously. Those born in the late 1990s were only expected to live into their early 30s. Back in 1955, children with cystic fibrosis rarely reached adulthood. 

Now, 60% of people with the disease are adults who are capable of going to college, pursuing careers, and starting families. Advances in care have turned life’s simple pleasures into major wins too, such as cystic fibrosis patients having enough energy to blow up a balloon and keep up with their kids on a soccer field.

The disease is complex and affects everyone in different ways and to varying degrees. It’s caused by mutations in a specific gene that lead to a buildup of thick and sticky mucus in various organs. Mucus in the lungs clogs the airways and traps germs, leading to infections and difficulty breathing; mucus in the pancreas prevents the body from absorbing nutrients from food, resulting in malnutrition and poor growth; and mucus in the liver can cause liver disease. 

Common symptoms of cystic fibrosis include persistent coughing, frequent lung infections such as pneumonia and bronchitis, wheezing, greasy or bulky stools, chronic sinus infections, enlarged fingertips and toes, rectal prolapse (when part of the large intestine slips outside the anus), salty-tasting skin, and difficulty with bowel movements.  

Most people are diagnosed by age 2, but some are diagnosed as adults. Cystic fibrosis is the most common, life-threatening genetic condition in the US.

Fortunately, new treatments and expansions in eligibility for therapies have resulted in immense improvements in patients’ quality of life. 

In the last two years, there’s been a substantial decrease in worsening lung symptoms in people with cystic fibrosis. In 2019, exacerbations were reported in 41% of adults and 22% of children. In 2021, those percentages dropped to 14% and 10%, respectively. 

Experts say the pandemic increased awareness of infection prevention and the use of Trikafta, the brand name for a combination of three medications known as “cystic fibrosis transmembrane conductance regulator modulator therapies.” They work by correcting malfunctions in a specific protein caused by gene mutations. 

There are four different CFTR modulators: Trikafta (elexacaftor/tezacaftor/ivacaftor), Symdeko (tezacaftor/ivacaftor), Orkambi (lumacaftor/ivacaftor), and Kalydeco (ivacaftor).

Lung transplants have also decreased dramatically since 2016, when 271 people with cystic fibrosis were reported to receive one. In 2021, only 52 people had the procedure. 

Other therapies available for those with cystic fibrosis include clearing airways to loosen and remove thick mucus from the lungs, inhaling medicines to open the airways and fight infections, and taking pancreatic enzyme supplements to improve nutrient absorption. 

Many of these treatments require out-of-pocket costs, however. Data show that 41% of all people with cystic fibrosis and 52% of children under age 10 are on Medicaid, the government-funded health insurance for people with limited income and resources.

Source link

interstid / Getty Images

interstid / Getty Images

Pneumothorax, a collapsed lung, occurs when air escapes the lung and leaks into the space between the lung and the chest wall. The air puts pressure on the lung, which prevents it from expanding normally when you inhale. Chest injuries, lung diseases, and activities that involve air pressure changes (e.g., scuba diving) can cause pneumothorax. The most common symptoms are sharp, sudden chest pain and shortness of breath.

Healthcare providers use imaging and blood tests to diagnose pneumothorax, which affects about 5 million people in the U.S. annually. Treatment may involve supplemental oxygen therapy or using a needle or chest tube to remove the air from the chest cavity and allow the lung to re-expand, depending on the severity of the lung collapse.

Types of Pneumothorax

There are different types of pneumothorax, which are classified based on what causes the lung to collapse:

  • Primary spontaneous pneumothorax: Occurs without any known cause in people who do not have an underlying lung disease.

  • Secondary spontaneous pneumothorax: Occurs in people with a lung disease, such as chronic obstructive pulmonary disease (COPD), tuberculosis, or cystic fibrosis.

  • Trauma-related pneumothorax: Occurs due to a traumatic injury to the chest, such as a rib fracture, car accident, or a fall.

  • Iatrogenic pneumothorax: A complication of a medical procedure, such as a lung biopsy or mechanical ventilation. Symptoms and treatment are similar to injury-related pneumothorax.

  • Catamenial pneumothorax: A rare type of pneumothorax that occurs in menstruating people with endometriosis. When endometrial tissue grows outside the uterus and into the chest cavity, blood can build up in the chest cavity, causing it to collapse.


Symptoms of pneumothorax can range in severity from mild to life-threatening. Common symptoms include:

  • Sharp, sudden chest pain which may be felt on only one side of the chest and feel worse when taking a deep breath or coughing

  • Shortness of breath—it may feel like you can’t catch your breath or you’re not getting enough air

  • Rapid breathing and heart rate

  • Bluish skin or lips due to a lack of oxygen

  • Dry cough

If you have symptoms of pneumothorax, seek immediate medical attention. In some cases, pneumothorax can be life-threatening, and early diagnosis and treatment can help prevent complications.


Pneumothorax occurs when air leaks into the pleural cavity—the space between the lung and the chest wall. Air building up in this space puts pressure on the lung, causing a full or partial collapse.

In some cases, pneumothorax can occur without any known cause, but it is most often caused by lung disease, injury, and lifestyle factors.

Primary Spontaneous Pneumothorax (PSP) Causes

PSP occurs in people with no underlying lung disease and is most common in healthy young adults. Researchers aren’t sure of the exact cause of PSP, but it is most likely due to the formation of small air-filled sacs on the lung surface, known as blebs. When blebs rupture, air can leak into the chest cavity, put pressure on the lung and cause it to collapse.

Secondary Spontaenous Pneumothorax (SSP) Causes

SSP is often caused by an underlying lung disease that weakens lung tissue and increases the risk of pneumothorax. Lung diseases that can cause pneumothorax include:

Traumatic Pneumothorax Causes

Traumatic pneumothorax occurs when the chest is injured, such as during a car accident, or from a gunshot or rib fracture. If the lung becomes punctured during certain medical procedures, such as lung biopsy or nerve block, it may lead to lung collapse.

Other Causes

Certain lifestyle factors can also cause pneumothorax, including:

  • Pressure changes, such as during scuba diving or traveling at high altitudes

  • Recreational drug use, especially inhaled drugs such as cannabis, cocaine, and methamphetamines

  • Smoking

  • Menstruation, especially in people with endometriosis

Risk Factors

Certain risk factors increase the risk of developing pneumothorax, including:

  • Smoking: Smoking tobacco, cannabis, and vaping can significantly increase the risk of lung collapse.

  • Sex: Men are more likely to be affected, especially those who are tall and thin.

  • Family history: About 1 in 10 people who experience spontaneous pneumothorax with no known cause have a family history of the condition.

How Is Pneumothorax Diagnosed?

To diagnose pneumothorax, your healthcare provider will ask about your symptoms, perform a physical examination, and evaluate your medical history. During the exam, they will listen to your lungs to hear decreased breathing sounds on one side of your chest. They will also watch your chest as you breathe to determine if one side rises and falls normally and the other doesn’t.

If your healthcare provider suspects your lung has collapsed, they may order diagnostic tests to confirm the diagnosis. The primary diagnostic tests include imaging tests and blood tests.

In terms of imaging tests, a chest X-ray, ultrasound, or computed tomography (CT) scan can help visualize the lung and chest cavity to look for a collapsed lung.

For blood tests, arterial blood gas testing measures the amounts of oxygen and carbon dioxide in the bloodstream. Too low oxygen levels (hypoxemia) or too high carbon dioxide levels (hypercapnia) are indicators of pneumothorax.


The goal of treatment for pneumothorax is to remove the air from the space between the lung and chest wall to allow the lung to re-expand and restore normal breathing. The specific treatment approach depends on the severity and underlying cause of lung collapse.

For small, uncomplicated pneumothorax, observation and monitoring may be sufficient. For larger and more severe pneumothorax, treatment may include:

  • Supplemental oxygen: If your pneumothorax is small, you may be given supplemental oxygen to ensure your body gets enough oxygen until the lung collapse resolves on its own within several weeks.

  • Needle aspiration: A thin needle attached to a syringe is inserted between the ribs into the pleural space to remove the excess air.

  • Chest tube insertion: A hollow tube is inserted through the chest wall into the pleural space to remove air and allow the lung to re-expand. The tube is left in place for several hours to days to allow the lung to fully re-inflate and prevent the lung from collapsing again.

  • Pleurodesis: If pneumothorax was caused by injury or you have repeated episodes of lung collapse, pleurodesis may be performed. This involves inserting a tube and adding chemicals (e.g., talc or doxycycline) to help the lung attach to the chest wall and prevent future collapse.

  • Surgery: In severe cases, surgery may be necessary to repair the lung and prevent pneumothorax recurrence. This may involve a thoracoscopy, a procedure that involves making a small incision in the chest to allow the surgeon to view the lung and remove damaged tissue. The surgeon may also attach the lung to the chest wall with gauze or chemicals (e.g., talc) to prevent a recurrence.

How to Prevent Pneumothorax

There are no specific ways to primary spontaneous pneumothorax because it usually occurs without an identifiable cause. However, certain measures can reduce the risk of developing secondary spontaneous and injury-related pneumothorax. These include:

  • Manage underlying lung conditions: If you have a lung condition such as COPD, asthma, or cystic fibrosis, work with your healthcare provider to manage your condition and follow your treatment plan as recommended.

  • Quit smoking: Smoking is a major risk factor for lung disease and can increase the risk of pneumothorax.

  • Avoid scuba diving and flying: Activities that involve drastic changes in air pressure, such as scuba diving and airplane travel, can increase the risk of pneumothorax. Avoiding these activities if you have a history of pneumothorax or are healing from a recent lung collapse is especially important.

Comorbid Conditions

Pneumothorax is often associated with certain comorbid conditions or underlying medical conditions. In addition to lung diseases, certain conditions increase the risk of pneumothorax:

  • Lung diseases such as COPD, asthma, and tuberculosis

  • Connective tissue disorders, such as Marfan syndrome and Ehlers-Danlos syndrome

  • Familial spontaneous pneumothorax, a rare inherited condition that runs in families and is characterized by recurrent episodes of spontaneous pneumothorax

  • Hypertension (high blood pressure)

  • Diabetes

Research shows that people who a history of pneumothorax are at an increased risk of developing lung cancer. Those who have experienced spontaneous pneumothorax more than twice per year have a more than 30-fold higher risk of lung cancer than those with no history of lung collapse.

Living with Pneumothorax

Experiencing a pneumothorax can be a scary experience, especially if it causes symptoms like trouble breathing and sharp chest pain. Fortunately, most people with pneumothorax recover without major treatment and long-term complications.

After an episode of pneumothorax, there is a 21-54% risk of it happening again within 1-2 years. If you have a history of pneumothorax or certain factors that increase your risk, you may need to avoid certain activities, such as scuba diving or high-altitude flying. In some cases, people with recurrent pneumothorax may need surgery to attach the lungs to the chest wall to prevent future episodes.

For more Health news, make sure to sign up for our newsletter!

Read the original article on Health.

Source link

Visiongain has published a new report entitled Therapeutic Respiratory Devices 2023-2033: Forecasts by Product (Inhalers (Metered Dose Inhalers, Dry Powder Inhalers, Soft Mist Inhalers), Ventilators (Adult Ventilators, Neonatal Ventilators), Humidifiers (Heated Humidifiers, Passover Humidifiers, Integrated Humidifiers, Built-in Humidifiers, Stand-alone Humidifiers), Positive Airway Pressure Devices (Continuous Positive Airway Pressure Devices, Auto-titrating Positive Airway Pressure Devices, Bi-level Positive Airway Pressure Devices), Oxygen Concentrators (Fixed Oxygen Concentrators, Portable Oxygen Concentrators), Nebulizers (Compressor-based Nebulizers, Piston-based Hand-held Nebulizers, Ultrasonic Nebulizers)), by Application (Asthma, Chronic Obstructive Pulmonary Disease, Cystic Fibrosis, Acute Respiratory Failure, Obstructive Sleep Apnea, Respiratory Distress Syndrome, Others), by End-users (Homecare Settings, Hospitals, Others), by Distribution Channel (Retail Pharmacies, Hospitals Pharmacies, Online Pharmacies) AND Regional and Leading National Market Analysis PLUS Analysis of Leading Companies AND COVID-19 Impact and Recovery Pattern Analysis 

The global therapeutic respiratory devices market was valued at US$59.49 billion in 2022 and is projected to grow at a CAGR of 8.02% during the forecast period 2023-2033. 

Rising Geriatric Population Projected to Boost Market Growth 

An ageing population is more prone to suffer from age-related health difficulties such as cardiovascular disease, neurological diseases, diabetes, and a range of respiratory ailments. Consumers' desire to live a healthy lifestyle adds to a rise in demand for respiratory equipment. For the first time, the number of persons aged 65 and over outnumbers those under the age of five. The population will continue to age as fertility rates fall and life expectancy rises. The number of people aged 65 and more is predicted to reach about 1.5 billion by 2050. 

Low and middle income countries account for the vast majority of asthma-related fatalities. People have been able to live longer lives as a result of improved health care and a greater level of life. The challenge of an ageing population is no longer limited to the most industrialised countries. Older individuals are becoming increasingly numerous in emerging nations at a higher rate than in developed economies. People's level of life is rising as the economy and riches expand. Infrastructure and healthcare systems in the country can also be improved. 

Download Exclusive Sample of Report

How has COVID-19 had a Positive Impact on the Therapeutic Respiratory Devices Market? 

The COVID-19 outbreak has expedited the development of new and portable respiratory medicine delivery devices, with a boost in remote and at-home trial activities, as well as patient purchases for home-care settings. Due of the COVID-19 epidemic, numerous countries' supplies of respiratory treatments and drug delivery technologies were insufficient to address the expanding number of patients. There was a substantial danger of patient death due to a shortage of resources such as breathing equipment, medical supplies, and staff. As a result, patients were compelled to stay at home and gather their own resources, which hampered the procurement of respiratory medications and delivery devices such as nebulizers, inhalers, and other portable devices. 

How will this Report Benefit you? 

Visiongain’s 452-page report provides 183 tables and 300 charts/graphs. Our new study is suitable for anyone requiring commercial, in-depth analyses for the therapeutic respiratory devices market, along with detailed segment analysis in the market. Our new study will help you evaluate the overall global and regional market for Therapeutic Respiratory Devices. Get financial analysis of the overall market and different segments including type, invasive procedure type, non-invasive procedure type, gender, end-user, and capture higher market share. We believe that there are strong opportunities in this fast-growing therapeutic respiratory devices market. See how to use the existing and upcoming opportunities in this market to gain revenue benefits in the near future. Moreover, the report will help you to improve your strategic decision-making, allowing you to frame growth strategies, reinforce the analysis of other market players, and maximise the productivity of the company. 

What are the Current Market Drivers? 

Rising Demand for Homecare Therapeutic Respiratory Devices is Driving the Market Growth   

Companies are developing homecare services in response to the demand for homecare settings, such as replenishment systems and leasing services. CHI health is one such firm that offers low-cost gadgets and services that allow patients to obtain treatment and care in the comfort of their own homes. Sleep apnea therapy equipment must be maintained and updated on a regular basis in order to ensure pleasant, effective sleep apnea therapy. Patients suffering from sleep apnea may now replace their PAP equipment on schedule thanks to Resmed's restocking programme. Over time, this enhances patient satisfaction and adherence. More patients are being enrolled in automated replenishment schemes.  

Rising Funding by Government Organizations and Healthcare Companies is Creating Opportunities for Market Expansion  

Several government organisations and businesses run awareness programmes to promote understanding about asthma kinds and quick safety advice in order to avoid the condition from becoming severe. Cipla's launch in August 2022 of a patient awareness campaign in India dubbed BerokZindagi is one example. Due to the Berok Zindagi campaign, inhalers and asthma have been vilified and misunderstood. It has substantially helped to greater knowledge and adoption of inhalers throughout the years. As part of the campaign, some people have come forward to tell their asthma tales, which will help to create a more accepting attitude about inhalers. 

Download Exclusive Sample of Report

Where are the Market Opportunities? 

Digital Platform for Respiratory Related Therapies Anticipated to Spur Industry Growth 

Asthma, COPD, and other related disorders cost the healthcare system more than $130 billion each year. While there may be possibilities in the respiratory room, treating for these illnesses comes with its own set of problems, including the fact that they are difficult to assess. Companies around the world are developing digital platforms for respiratory-related therapies, such as AptarGroup, Inc. and Sonmol, a Chinese digital respiratory therapeutics firm, which announced a partnership on April 21, 2020, to create a digital therapies and services network targeting respiratory and other diseases. Aptar Pharma's relationship with Sonmol is expected to greatly boost Aptar's digital health solutions in Asia. 

Competitive Landscape 

The major players operating in the therapeutic respiratory devices market are 3M Health Care, Airsep Corporation (Chart Industries), AptarGroup, Inc., AstraZeneca, Becton, Dickinson and Company (BD), Boehringer Ingelheim International GmbH, Cipla Inc., Fisher & Paykel Healthcare Limited, GE Healthcare, GF Health Products, Inc., GSK plc, Hamilton Medical, Invacare, Koninklijke Philips N.V., Medisana GmbH, Medtronic, Merck & Co., Inc., Novartis AG, OMRON Corporation, Recipharm AB, ResMed, Shenzhen Mindray Bio-Medical Electronics Co., Ltd., Smiths Medical, Inc., Sunovion Pharmaceuticals Inc., and Teva Pharmaceutical Industries Ltd. These prominent competitors in the therapeutic respiratory devices market have pursued various tactics such as M&A, partnerships, geographical growth, R&D investment, and new product introduction. 

Recent Developments 

  • In October 2022, Merck & Co. established a packaging facility in Singapore to support its best-selling cancer medication and vaccine, while also starting work on a factory to manufacture next-generation inhalers. 
  • In July 2022, Transpire Bio signed a final agreement with Recipharm to develop TRB-1 and TRB-2, inhaled medications for the treatment of COPD and asthma. 

To access the data contained in this document please email [email protected]

To find more Visiongain research reports on the Pharma sector, click on the following links: 

Do you have any custom requirements we can help you with? Any need for a specific country, geo region, market segment or specific company information? Contact us today, we can discuss your needs and see how we can help: [email protected]

About Visiongain 

Visiongain is one of the fastest-growing and most innovative independent market intelligence providers around, the company publishes hundreds of market research reports which it adds to its extensive portfolio each year. These reports offer in-depth analysis across 18 industries worldwide. The reports, which cover 10-year forecasts, are hundreds of pages long, with in-depth market analysis and valuable competitive intelligence data. Visiongain works across a range of vertical markets with a lot of synergies. These markets include automotive, aviation, chemicals, cyber, defence, energy, food & drink, materials, packaging, pharmaceutical and utilities sectors. Our customised and syndicated market research reports offer a bespoke piece of market intelligence customised to your very own business needs. 


Oliver Davison
Visiongain Reports Limited 
Telephone: +44 (0) 20 7336 6100 
Email: [email protected]

Source link

Starting in 2024, individuals with cystic fibrosis will no longer automatically qualify to receive a wish from the Make-A-Wish Foundation.

The nonprofit organization grants wishes to children who have been diagnosed with critical illnesses or conditions that jeopardize their life. 

Make-A-Wish said its decision to stop automatically providing wishes for those with cystic fibrosis is because of advancements in research and treatment for the genetic condition that causes problems with breathing and digestion. 

According to the Centers for Disease Control, cystic fibrosis affects about 35,000 people in the U.S. The life expectancy or those with cystic fibrosis has continually gone up. For those born between 1995-1999, the life expectancy was 32 years, according to the Cystic Fibrosis Foundation. Babies born between 2015-2019 now have a life expectancy of 46 years.

Make-A-Wish said it wouldn't automatically reject wishes for children with cystic fibrosis. Instead, it said the wishes will be granted on a case-by-case basis. 

"This is consistent with our approach to other critical illnesses that do not automatically qualify for wishes because the course of the condition varies from person to person," the organization stated. 

The nonprofit added that it grants wishes on a case-by-case basis for individuals with other illnesses, including certain types of cancer, epilepsy and heart disease. 

Source link

Breathing Exercise Machine Market

Breathing Exercise Machine Market

The Breathing Exercise Machine Market refers to the market for devices designed to help individuals improve their respiratory function through breathing exercises. These machines are commonly used by people who suffer from conditions that affect their lung function, such as asthma, COPD (Chronic Obstructive Pulmonary Disease), and cystic fibrosis.

Breathing exercise machines come in various forms, including handheld devices, masks, and machines that simulate high-altitude environments. Some machines also incorporate additional features such as vibration, sound therapy, and aromatherapy to enhance the effectiveness of breathing exercises.

Additional Details on welding equipment market:

Key Questions for Welding Equipment Market:

1) What are the challenges faced by the breathing exercise machine market?
Ans. The market faces the challenge of limited awareness about the benefits of breathing exercise machines among potential customers, particularly in developing countries. This can limit the adoption of these devices, thereby hindering market growth. Some breathing exercise machines are expensive, which can make them inaccessible to people with lower incomes.

2) What are the potential opportunities for growth in the breathing exercise machine market?
Ans. The increasing prevalence of respiratory diseases, such as COPD, asthma, and cystic fibrosis, is a major driver for the growth of the breathing exercise machine market. As the number of people suffering from respiratory diseases continues to rise, the demand for breathing exercise machines is also expected to increase.

3) What are the current applications and limitations of liquid biopsy in clinical practice?
Ans. Wearable devices that help users improve their respiratory function through breathing exercises are gaining popularity. Portable and compact breathing exercise machines are becoming increasingly popular, particularly among people who travel frequently or have limited space at home. Virtual reality-based breathing exercise machines are designed to provide a more immersive and engaging experience for users. Smart breathing exercise machines are equipped with sensors and AI-powered algorithms that can track a user's progress and provide personalized feedback.

Some Key trends:

• Increasing Adoption of Non-Invasive Therapies: There is a growing trend towards non-invasive therapies, including breathing exercises, as people seek out alternative treatment options that are less invasive and have fewer side effects than medication or surgery.
• Personalized Breathing Exercises: Personalization is becoming a key trend in the breathing exercise machine market, with devices being designed to provide tailored exercises based on the user's respiratory function, age, and overall health status.
• Emphasis on Ease of Use: Manufacturers are focusing on designing breathing exercise machines that are easy to use, with simple interfaces and clear instructions. This trend is driven by the growing popularity of at-home respiratory therapy, particularly among older adults.
• Rising Demand for Home-based Respiratory Therapy: The COVID-19 pandemic has accelerated the trend towards home-based respiratory therapy, with more people opting to exercise their lungs from the comfort of their own homes.

Access to the Free Sample Report:

Top Key Players for Polyester Fiber Market:

The Breathing Exercise Machine Market is highly competitive, with a large number of players offering a wide range of products and services. Key factors that can differentiate companies in this market include product quality, innovation, pricing, and distribution.

• Becton, Dickinson and Company
• Cardinal Health
• Smith's Medical
• Nidek Medical India
• Teleflex Incorporated
• Kompaniya Dinamika
• Wintersweet Medical
• Boen Healthcare
• Beijing Konted Medical Technology

Market Segmentation, By Type- Three Flow Breathing Exercise Devices, Two flow Breathing Exercise Devices, Single Flow Breathing Exercise Devices, and Disposable Incentive Spirometers

Market Segmentation, By Function- Inspiratory Breathing Exercise Devices and Volumetric Breathing Exercise Devices

Market Segmentation, By Application- Hospitals, Clinics, Home Care Settings, and Athlete use

Regional Analysis

North America - U.S., Canada
Europe - UK, Germany, France, Italy, Russia, Rest of Europe
Asia Pacific - Japan, India, China, South Korea, Rest of Asia-Pacific
Latin America - Brazil, Mexico, Rest of Latin America
Middle East & Africa - GCC, South Africa, UAE, Rest of Middle East.

Similar Reports:

To know more
Contact Us:
Prophecy Market Insights
1 860 531 2701
Email- [email protected]

About Us:
Prophecy Market Insights is specialized market research, analytics, marketing/business strategy, and solutions that offers strategic and tactical support to clients for making well-informed business decisions and to identify and achieve high-value opportunities in the target business area. We also help our clients to address business challenges and provide the best possible solutions to overcome them and transform their business.

This release was published on openPR.

Source link

New York, United States, March 14, 2023 (GLOBE NEWSWIRE) -- Cystic fibrosis is a genetic condition that mostly impacts the lungs but can also impact other organs and systems in the body such as the pancreas, liver, and kidneys. This condition is brought on by a mutation in the CFTR gene, which stands for cystic fibrosis transmembrane conductance regulator. This gene, which is found on chromosomal number 7, is important for regulating perspiration, mucus, and other bodily fluids. Its location is on chromosome number 7. However, mutation of this gene leads to absence of CFTR function, which in turn leads to loss of chloride and changes the structure of the protein. This is a consequence of the chain reaction that begins when this gene is mutated. Patients suffering from this condition have trouble breathing, the development of mucus, the pathway of the pancreas, the bile duct, the gut, and the salivary gland are all affected by the difficulties. The sweat test and genetic testing are the two primary methods for diagnosing cystic fibrosis. The treatment of cystic fibrosis includes the use of physical therapy, which assists in the decrease of mucus formation and fights against infections of an organ.

Get a Free Sample Copy of This Report @

The market will expand as cystic fibrosis treatments become more widely known and accepted

A significant element that is anticipated to promote the advancement of the market is the growing awareness in developing nations regarding the oral medication therapies for diseases like cystic fibrosis, such as pancreatic enzyme supplements and CFTR modulators, and the cost affordability of these medicines. Cystic fibrosis is a condition that can cause damage to the lungs and other organs in the body. To improve the overall state of public health, a great number of healthcare organisations and medical institutes are working to raise knowledge about the treatment of cystic fibrosis.

Access to more advanced treatment options will encourage market expansion

The industry has been sparked by a rise in the number of cystic fibrosis patients worldwide. Cystic fibrosis pharmacotherapy has led to a number of advancements in the treatment of this condition, which is positively affecting market growth. The industry's rise is also being fuelled by market trends that are now being used in the treatment of the ailment. This is because a growing number of candidates for therapeutic treatment are being produced by important corporations and are now in the pipeline. As a result, pharmaceutical firms are being urged to create novel therapies that target flaws in the CFTR protein. Additionally, the launch of Ivacaftor/Lumacaftor, a potentiator that improves quality of life for individuals who suffer from the ailment, is also assisting in the market's growth.

Rising CF Incidence to Support Market Growth

Cystic Fibrosis is becoming the most prevalent genetic illness in every region of the world. This frequently influences several organ systems across the body. According to the Cystic Fibrosis Patient Registry, it is believed that more than 30,000 persons in the United States are now afflicted with this ailment, and it is projected that around 70,000 people throughout the world are afflicted with this condition. In addition to this, it is also mentioned that each year there are roughly 1,000 new cases of the condition that are identified. As a result, it is anticipated that the growing frequency of respiratory issues, gastrointestinal complications, and reproductive diseases in patients with CF would also contribute to an increase in the demand for the treatment of the illness throughout the course of the projection period.

Potential Pipeline Candidates Existence to Accelerate Market Growth

The imminent arrival of new medications for the treatment of cystic fibrosis (CF) is a welcome development that is contributing to the expansion of the market. During the time period in question, the development of new pharmaceuticals that are targeting the deficiency in cells of people who are afflicted with illnesses is expected to boost the growth of the market. The fact that this treatment is expected to be transformative for a great number of patients is driving the expansion of the market. In addition, a growth in the number of people who are affected by the condition is believed to be the most important element driving the market. Because of this, the launch of freshly developed pipeline pharmaceuticals that are necessary for the treatment of very ill patients is gaining momentum. In addition to this, many possible candidates are now in their last phases of development and are forecasting the expansion of the market soon.

Report Scope

Report Metric Details
Market Size USD 13.88 billion by 2030
CAGR 9.12% (2022-2030)
Historical Data 2019-2020
Base Year 2021
Forecast Period 2022-2030
Forecast Units Value (USD Billion)
Report Coverage Revenue Forecast, Competitive Landscape, Growth Factors, and Trends
Segments Covered By Drug Class, By Route of Administration, By Region
Geographies Covered North America, Europe, Asia-Pacific, LAME and Rest of the World
Key Companies Profiled/Vendors Vertex Pharmaceutical Incorporated, Roche, Nestle Health Science, AbbVie, Viatris Inc., Horizon Therapeutic Plc., Gilead Sciences, Chiesi Farmacrutici, Pharmaxis Ltd., Teva Pharmaceuticals
Key Market Drivers The market will expand as cystic fibrosis treatments become more widely known and accepted

Access to more advanced treatment options will encourage market expansion

Rising CF Incidence to Support Market Growth

Buy Now Full Report @

Regional Overview of Cystic Fibrosis Therapeutics Market

The market is divided into five regions based on geography: North America, Europe, Asia Pacific, Latin America, and the Middle East and Africa. In 2016, North America brought in the most money, $2,396.4 million. The majority of those affected by CF are of Caucasian heritage, making North America the region where CF is most common. Additionally, one of the main factors that may be attributed for its highest share is actions conducted by the CF Foundation and Cystic Fibrosis Canada.

With a profitable growth rate of 18.8 percent, Asia Pacific is anticipated to expand at the quickest rate. Due to underdiagnosis and a lack of country-specific CF patient registries, the incidence of CF is less frequently reported in the Asia Pacific region. Nevertheless, over the course of the forecast period, rising awareness about CF disorders and treatment options is anticipated to drive this segment.

Key Highlights

  • The global market for Cystic Fibrosis Therapeutics is expected to reach USD 13.88 billion in 2030 expanding at a CAGR of 9.12%.
  • The market will expand as cystic fibrosis treatments become more widely known and accepted
  • Potential Pipeline Candidates Existence to Accelerate Market Growth
  • Rising CF Incidence to Support Market Growth
  • Access to more advanced treatment options will encourage market expansion
  • Maintaining lung function while controlling respiratory infection and cleaning mucus from airways, regulating nutritional therapy, and limiting complications are the basic concerns in the management of cystic fibrosis (CF). In the year 2012, the pharmaceutical company Kalydeco became the first company to commercialise a CFTR modulator medication.
  • In 2016, the oral route had the biggest share—nearly 63.7 percent—due to the benefits of its administration, including simplicity and ease of consumption without the assistance of a healthcare expert.
  • CFTR modulators like KALYDECO and ORKAMBI and pancreatic enzyme supplements like Creon/Zenpep, PERTZYE, Ultresa, and Viokace are a few of the authorised therapies that are taken orally.
  • In 2016, North America brought in the most money, $2,396.4 million. The majority of those affected by CF are of Caucasian heritage, making North America the region where CF is most common.

Competitors in Cystic Fibrosis Therapeutics Market

  1. Vertex Pharmaceutical Incorporated
  2. Roche
  3. Nestle Health Science
  4. AbbVie
  5. Viatris Inc.
  6. Horizon Therapeutic Plc.
  7. Gilead Sciences
  8. Chiesi Farmacrutici
  9. Pharmaxis Ltd.
  10. Teva Pharmaceuticals

Are a few of the well-known businesses participating in the sector? To maintain the level of industry rivalry, these market participants are putting numerous growth plans into practise.

Get a Free Sample Copy of This Report @

Segmentation of Cystic Fibrosis Therapeutics Market

By Drug Class

  • Pancreatic Enzyme Supplements
  • Mucolytics
  • Bronchodilators
  • CFTR Modulators

By Route of Administration

By Region

  • North American
  • Europe
  • Asia Pacific
  • Latin America
  • Middle east


    1. Research Objectives
    2. Market Definition
    3. Limitations & Assumptions
    4. Market Scope & Segmentation
    5. Currency & Pricing Considered
    1. Emerging Regions / Countries
    2. Emerging Companies
    3. Emerging Applications / End Use
    4. Investment Landscape
    5. New Business Models / Revenue Streams
    6. TAM
    1. Drivers
    2. Market Warning Factors
    3. Latest Macro Economic Indicators
    4. Geopolitical Impact
    5. Human Factors
    6. Technology Factors
    1. Porters Five Forces Analysis
    2. Value Chain Analysis
    3. Sales And Distribution Channel Analysis
    4. Case Study Analysis
    5. Patent Analysis
    6. M & A Agreements & Collabration Analysis
    1. Global Cystic Fibrosis Therapeutics Market Introduction
    2. By Drug Class
      1. Introduction
        1. Drug Class By Value
      2. Pancreatic Enzyme Supplements
        1. By Value
      3. Mucolytics
        1. By Value
      4. Bronchodilators
        1. By Value
      5. CFTR Modulators
        1. By Value
    3. By Route Of Administration
      1. Introduction
        1. Route Of Administration By Value
      2. Oral Drugs
        1. By Value
      3. Inhaled Drugs
        1. By Value
    1. Introduction
    2. By Drug Class
      1. Introduction
        1. Drug Class By Value
      2. Pancreatic Enzyme Supplements
        1. By Value
      3. Mucolytics
        1. By Value
      4. Bronchodilators
        1. By Value
      5. CFTR Modulators
        1. By Value
    3. By Route Of Administration
      1. Introduction
        1. Route Of Administration By Value
      2. Oral Drugs
        1. By Value
      3. Inhaled Drugs
        1. By Value
    4. U.S.
      1. By Drug Class
        1. Introduction
          1. Drug Class By Value
        2. Pancreatic Enzyme Supplements
          1. By Value
        3. Mucolytics
          1. By Value
        4. Bronchodilators
          1. By Value
        5. CFTR Modulators
          1. By Value
      2. By Route Of Administration
        1. Introduction
          1. Route Of Administration By Value
        2. Oral Drugs
          1. By Value
        3. Inhaled Drugs
          1. By Value
    5. Canada
    1. Introduction
    2. By Drug Class
      1. Introduction
        1. Drug Class By Value
      2. Pancreatic Enzyme Supplements
        1. By Value
      3. Mucolytics
        1. By Value
      4. Bronchodilators
        1. By Value
      5. CFTR Modulators
        1. By Value
    3. By Route Of Administration
      1. Introduction
        1. Route Of Administration By Value
      2. Oral Drugs
        1. By Value
      3. Inhaled Drugs
        1. By Value
    4. U.K.
      1. By Drug Class
        1. Introduction
          1. Drug Class By Value
        2. Pancreatic Enzyme Supplements
          1. By Value
        3. Mucolytics
          1. By Value
        4. Bronchodilators
          1. By Value
        5. CFTR Modulators
          1. By Value
      2. By Route Of Administration
        1. Introduction
          1. Route Of Administration By Value
        2. Oral Drugs
          1. By Value
        3. Inhaled Drugs
          1. By Value
    5. Germany
    6. France
    7. Spain
    8. Italy
    9. Russia
    10. Nordic
    11. Benelux
    12. Rest Of Europe
    1. Introduction
    2. By Drug Class
      1. Introduction
        1. Drug Class By Value
      2. Pancreatic Enzyme Supplements
        1. By Value
      3. Mucolytics
        1. By Value
      4. Bronchodilators
        1. By Value
      5. CFTR Modulators
        1. By Value
    3. By Route Of Administration
      1. Introduction
        1. Route Of Administration By Value
      2. Oral Drugs
        1. By Value
      3. Inhaled Drugs
        1. By Value
    4. China
      1. By Drug Class
        1. Introduction
          1. Drug Class By Value
        2. Pancreatic Enzyme Supplements
          1. By Value
        3. Mucolytics
          1. By Value
        4. Bronchodilators
          1. By Value
        5. CFTR Modulators
          1. By Value
      2. By Route Of Administration
        1. Introduction
          1. Route Of Administration By Value
        2. Oral Drugs
          1. By Value
        3. Inhaled Drugs
          1. By Value
    5. Korea
    6. Japan
    7. India
    8. Australia
    9. Taiwan
    10. South East Asia
    11. Rest Of Asia-Pacific
    1. Introduction
    2. By Drug Class
      1. Introduction
        1. Drug Class By Value
      2. Pancreatic Enzyme Supplements
        1. By Value
      3. Mucolytics
        1. By Value
      4. Bronchodilators
        1. By Value
      5. CFTR Modulators
        1. By Value
    3. By Route Of Administration
      1. Introduction
        1. Route Of Administration By Value
      2. Oral Drugs
        1. By Value
      3. Inhaled Drugs
        1. By Value
    4. UAE
      1. By Drug Class
        1. Introduction
          1. Drug Class By Value
        2. Pancreatic Enzyme Supplements
          1. By Value
        3. Mucolytics
          1. By Value
        4. Bronchodilators
          1. By Value
        5. CFTR Modulators
          1. By Value
      2. By Route Of Administration
        1. Introduction
          1. Route Of Administration By Value
        2. Oral Drugs
          1. By Value
        3. Inhaled Drugs
          1. By Value
    5. Turkey
    6. Saudi Arabia
    7. South Africa
    8. Egypt
    9. Nigeria
    10. Rest Of MEA
    1. Introduction
    2. By Drug Class
      1. Introduction
        1. Drug Class By Value
      2. Pancreatic Enzyme Supplements
        1. By Value
      3. Mucolytics
        1. By Value
      4. Bronchodilators
        1. By Value
      5. CFTR Modulators
        1. By Value
    3. By Route Of Administration
      1. Introduction
        1. Route Of Administration By Value
      2. Oral Drugs
        1. By Value
      3. Inhaled Drugs
        1. By Value
    4. Brazil
      1. By Drug Class
        1. Introduction
          1. Drug Class By Value
        2. Pancreatic Enzyme Supplements
          1. By Value
        3. Mucolytics
          1. By Value
        4. Bronchodilators
          1. By Value
        5. CFTR Modulators
          1. By Value
      2. By Route Of Administration
        1. Introduction
          1. Route Of Administration By Value
        2. Oral Drugs
          1. By Value
        3. Inhaled Drugs
          1. By Value
    5. Mexico
    6. Argentina
    7. Chile
    8. Colombia
    9. Rest Of LATAM
    1. Adoption Matrix
    2. Cystic Fibrosis Therapeutics Market Share By Manufacturers
    3. Cystic Fibrosis Therapeutics Market Ranking By Revenue For Manufacturers
    4. Average Price By Manufacturers
    5. Vendor Footprint Analysis
    1. Vertex Pharmaceutical Incorporated
      1. Overview
      2. Business Information
      3. Revenue
      4. ASP
      5. Gross Margin
      6. Swot Analysis
      7. Recent Developmments
    2. Roche
    3. Nestle Health Science
    4. AbbVie
    5. Viatris Inc.
    6. Horizon Therapeutic Plc.
    7. Gilead Sciences
    8. Chiesi Farmacrutici
    9. Pharmaxis Ltd.
    10. Teva Pharmaceuticals
    1. Research Data
      1. Secondary Data
        1. Major Secondary Sources
        2. Key Data From Secondary Sources
      2. Primary Data
        1. Key Data From Primary Sources
        2. Breakdown Of Primaries
      3. Secondary And Primary Research
        1. Key Industry Insights
    2. Market Size Estimation
      1. Bottom-Up Approach
      2. Top-Down Approach
      3. Market Projection
    3. Research Assumptions
      1. Assumptions
    4. Limitations
    5. Risk Assessment
    1. Discussion Guide
    2. Customization Options
    3. Related Reports

Table of Content @

Recent Development

For the treatment of cystic fibrosis patients regardless of CFTR genotype and other respiratory disorders, Roche announced the cooperation with AbbVie and the acquisition of the TMEM16A potentiators portfolio in October 2020. The relationship influenced the expansion of the company's product line.

A strategic agreement between AbbVie and The Cystic Fibrosis Foundation was established in October 2019 in order to create a CFTR potentiator molecule. The firm was able to broaden its product offering because to this relationship.

In November 2020, the Swiss-based biopharmaceutical firm Polyphor announced that it has reached a financial deal with the Cystic Fibrosis Foundation to develop the use of the novel antibiotic inhaled murepavadin in CF patients (cystic fibrosis).

The Hopkins University and Medicine researchers created a breakthrough of a novel antibiotic for a disease in December 2020. Mycobacterium abscesses is the pathogen, and it is harmful to those who have cystic fibrosis or lung diseases since it is drug resistant.

News Media

How AI Is Laying The Foundation In The Discovery Of Drugs?

Have a Look at the Related Research Report?

Melanoma Therapeutics Market: Information by Cancer Type (Superficial Spreading Melanoma, Nodular Melanoma), Diagnosis (Dermatoscopy, Blood Test), Treatment, and Region — Forecast till 2031

Hepatitis B Therapeutics Market: Information by Therapy (Chemotherapy, Nucleoside Analogue), Product Type (Hepatitis B Vaccine, Anti-Viral Drugs), and Region — Forecast till 2031

Crohn's Disease Therapeutics Market: Information by Drug Class (TNF-Alpha Inhibitors, 5-Aminosalicylates), Gender Type (Men, Women), Disease Type, and Region — Forecast till 2031

Urinary Tract Infection Therapeutics Market: Information by Drug (Penicillin and Combinations, Quinolones, Cephalosporin), Indication (Complicated UTI), and Region – Forecast till 2031

Leukemia Therapeutics Market: Information by Type (Acute Lymphocytic Leukemia (All)), Treatment (Targeted Drugs), Mode of Administration (Oral and Injectable), and Region - Forecast till 2031

About Straits Research Pvt. Ltd.

Straits Research is a market intelligence company providing global business information reports and services. Our exclusive blend of quantitative forecasting and trends analysis provides forward-looking insight for thousands of decision-makers. Straits Research Pvt. Ltd. provides actionable market research data, especially designed and presented for decision-making and ROI.

Whether you are looking at business sectors in the next town or crosswise over continents, we understand the significance of being acquainted with the client’s purchase. We overcome our clients’ issues by recognizing and deciphering the target group and generating leads with utmost precision. We seek to collaborate with our clients to deliver a broad spectrum of results through a blend of market and business research approaches.

For more information on your target market, please contact us below:

Phone: +1 646 480 7505 (the U.S.)

+91 8087085354 (APAC)

+44 208 068 9665 (the U.K.)

Email: [email protected]

Follow Us: LinkedIn | Facebook | Instagram | Twitter

Source link


Published March 11, 2023

The global Medical Nebuliser Market size was valued at USD 1.04 billion in 2021 and is projected to grow at a CAGR of 6.2% during the forecast period from 2022 to 2030.

Market Overview

Medical Nebuliser makes it easier for the drug to get into the lungs in the form of a mist. One of the main things driving the demand for nebulizers around the world is the rising number of people with respiratory diseases like COPD, asthma, and cystic fibrosis. The growth of the global nebulizer market has been driven by investments in and improvements to drug delivery devices. Nebulizers are becoming more popular because the number of older people and people with respiratory diseases is growing. The World Health Organization (WHO) says that chronic obstructive pulmonary disease affects about 65 million people around the world and kills about 3 million people each year. Also, about 262 million people around the world were thought to have asthma in 2019, and 461,000 people died in the same year. Breathing problems are becoming more common because pollution is getting worse, people are smoking more, and industrialization is happening quickly. The World Health Organization (WHO) says that about 90% of the world’s population breathes polluted air and that about 7 million people die every year because of pollution both inside and outside. Indirectly, these things are making the global nebulizer market grow. Estimates and forecasts of the size of the Medical Nebuliser market are given in terms of sales volume (K units) and revenue (million USD), with data from 2017 to 2030, with 2022 as the base year. This report breaks down the global Medical Nebuliser market into many different types. Regional market sizes are also given for products by type, by use, and by player. When figuring out how big the market was, we thought about how COVID-19 and other global crises would affect it.

Click Here For A Free Sample PDF Copy Of The Medical Nebuliser Market Latest Research Before Purchase:

Segment Analysis

Due to their low cost, jet nebulizers are expected to have the biggest share of the global nebulizer market over the next few years. Also, jet nebulizers have become the most popular type over the years because they are easy to use and deliver drugs effectively. Jet nebulizers work well for delivering medicines that can’t be given with dry powder inhalers or pressurised metered-dose inhalers. Nebulizers also come in different styles, such as jet nebulizers, corrugated tubes, collection bags, breath-enhanced jet nebulizers, jet nebulizers that are activated by breathing, and others. Over the next few years, the mesh nebulizers market is expected to grow in a way that is good for business. This is because these devices are small and technologically advanced, and drug loss is kept to a minimum. The market for mesh nebulizers is expected to keep growing, mostly because patients like them more, they work quickly, they are portable, and they are easy to use. Market penetration is also helped by the fact that mesh nebulizers are becoming more popular in the business world because they deliver drugs to the lungs more accurately and leave behind less drug. Omron Corporation’s MicroAIR U100 is small and ready to travel. It uses mesh technology. Philips Healthcare’s Aeroneb Go is a portable nebulizer that uses Aerogen’s vibration mesh technology for patients who need respiratory aerosol therapy.Because COPD is becoming more common, it is expected to have the biggest share of the global nebulizer market over the next few years. Nebulizers are now easier for patients to use and more portable thanks to recent technological advances. Also, nebulized versions of many types of medications are widely available. These include long-acting beta2-agonists (LABAs), long-acting muscarinic receptor antagonists, steroids, mucolytics, and antibiotics. People with COPD can use nebulizers outside of acute settings like clinics and hospitals because of these features. This makes the segment grow. Research and development (R&D) activities that companies do to improve technologies also help the segment grow. For example, in January 2021, Wellinks announced that a review board of the U.S. FDA had approved the wireless nebulizer for use by people with COPD. Wellinks’ goal is to change the way respiratory care is done for the whole population.

Based on types, the Medical Nebuliser Market is segmented into:

  • Pneumatic Nebuliser
  • Ultrasonic Nebuliser
  • Mesh Nebuliser

Based on application, the Medical Nebuliser Market is segmented into:


  • COPD
  • Cystic Fibrosis
  • Asthma

By End-user:

  • Hospitals
  • Clinics
  • Homecare Settings

By Portability:

  • Tabletop Nebulizer
  • Portable Nebulizer

Buy this Premium Research [email protected]

Industry News and Key Developments

In March 2021, the Japanese government gave PARI Pharma GmbH permission to use the LAMIRA nebulizer system to sell ARIKAYCE (amikacin liposome inhalation suspension). The system has a custom-made medication reservoir that holds 8.4 mL of medicine and an aerosol head with a valved aerosol chamber that is made for aerosolizing ARIKAYCE.
In March 2021, AireHealth and LucidAct Inc. worked together to integrate the LucidAct provider portal with AireHealth’s digital health solution to support remote management of COPD and other long-term respiratory conditions.

On the Basis of Region:

The global Medical Nebuliser market has been looked at in different parts of the world, like North America, Latin America, the Middle East, Asia-Pacific, Africa, Europe, and India. In the near future, this market will be led by the global Medical Nebuliser region.

Regional Analysis

Regional Medical Nebuliser Market coverage (Regional Status, Demand Forecast, Country Trends, etc.):

    • North America, Europe, China, Japan, Southeast Asia, India.
    • North America (USA, Canada, and Mexico).
    • Europe (Germany, France, UK, Russia and, Italy).
    • Asia-Pacific (China, Japan, Korea, India and, Southeast Asia).

Key segments covered in Medical Nebuliser Market include:

    • Medical Nebuliser Market Growth Drivers and Barriers.
    • Market Trends, Market Opportunities, Porter’s Five Forces Analysis.
    • Market Overview, Industry Development, Market Maturity, Value Chain Analysis.
    • Regional and Country Level Analysis.
    • Trends and Forecasts for Market Segments.
    • Market Analysis and Various Recommendations.
    • Key market forces.

Report Customization: This report will be customized to your needs for additional data up to 5 companies or 5 countries or nearly 40 analyst hours.

Key Market Participants in the Medical Nebuliser Market :

PARI GmbH, Omron, Drive DeVilbiss Healthcare, Philips, Yuwell, Leyi, Folee, Medel S.p.A, Briggs Healthcare, 3A Health Care, Trudell Medical International, GF Health Products, and others.


Contrive Datum Insights (CDI) is a global delivery partner of market intelligence and consulting services to officials at various sectors such as investment, information technology, telecommunication, consumer technology, and manufacturing markets. CDI assists investment communities, business executives, and IT professionals to undertake statistics-based accurate decisions on technology purchases and advance strong growth tactics to sustain market competitiveness. Comprising of a team size of more than 100 analysts and cumulative market experience of more than 200 years, Contrive Datum Insights guarantees the delivery of industry knowledge combined with global and country-level expertise.


Anna B. (Head Of sales) | Contrive Datum Insights
Contact No- IND: +91 9834816757 / CANADA: +1 (215) 297 4078
Email Id : [email protected]

This Press Release has been written with the intention of providing accurate market information which will enable our readers to make informed strategic investment decisions. If you notice any problem with this content, please feel free to reach us on [email protected]


Xherald is passionate about offering extensive coverage of global business news. Dedicated to creating every participant's notification, it reaches its own reader. Daily our experts offer fresh relevant information regarding what is actually occurring in Markets as well as Business. Our headlines are actually swiftly paced and extensive. Our distributor directory connects you with brand new products or services and its market situation from the most effective companies around the planet. Xherald is driven by its 500+ contributors coming from around the world. Xherald provides local as well as global market intelligence information coverage in sectors ranging from healthcare, IOT, chemicals and 17 more sectors. Our updates are quickly paced and detailed. The news we present is actually a mix of authentic content, community contributions and curated headlines announcements. All of the updates our company supplies must pass a strict criterion of genuineness, relevance and significance to our readers.

Source link

Guests stream into her backyard, clad like characters from the comedy show Schitt's Creek. Fairy lights are strung under a marquee, a live band plays soft music and champagne flows freely.

It's a joyous occasion for Fawn Kruger from Fourways in Johannesburg. Fawn is one of only 22 patients in South Africa whose transplanted lungs have survived for a decade.

Ten years ago, Fawn (35) was barely clinging to life.

Cystic fibrosis, a disease that affects the lungs, had weakened her lung capacity so much that she was permanently hooked up to an oxygen tank.

She was pale, painfully thin and very weak – a lung transplant was her only hope of survival.

On 5 March 2013 she got the call that would change her life: a healthy set of lungs had been found and Fawn was prepped for surgery for a double lung transplant.

Every year, she marks the date with a big party for her "lungaversary", as she puts it.

organ donor, organ transplant, lung transplant

Fawn’s father Mark Rogers was a dead ringer for Eugene Levy’s character Johnny Rose in Schitt’s Creek. The hit comedy show was the theme for her celebration. (PHOTO: Supplied)

READ MOREBlind Mpumalanga schoolboy gets sight restored with high-tech glasses

"We celebrate every year, and we do something different each year,” she tells YOU.

“We have a party because I'm alive and we reflect and remember my donor. While we’re celebrating another year of life, someone is mourning the death of their child so we're very grateful to the donor’s family for saying ‘yes’ because I wouldn’t be here today without them.” 

organ donor, organ transplant, lung transplant

Fawn and her husband, Travis Kruger, with some of their friends at the party. (PHOTO: Supplied)

Fawn was born in Zimbabwe and was diagnosed with cystic fibrosis when she was just a year old.

Most of her childhood was spent travelling to Johannesburg, where hospitals were better equipped to treat her condition.

As a teen she was admitted every three months for treatment, which included the use of a nebuliser to get oxygen to her lungs, physiotherapy and intravenous antibiotics. 

“It was like having a constant bronchitis infection every day of your life – it was exhausting and painful,” she says.

organ donor, organ transplant, lung transplant

She survived daily with a nebuliser before the life-saving transplant surgery. (PHOTO: Supplied)

In 2010 she relocated to South Africa because her lungs had deteriorated and the trips from Zimbabwe to Joburg were becoming too costly. 

Within two years of moving here, her condition became so grave that she could barely get out of bed.

She depended on an oxygen tube to breathe, a feeding tube was surgically inserted into her stomach so that she could get enough nutrients. She also needed an insulin machine to help manage her diabetes.

Because the veins in her arms had collapsed due to all her IV treatment, she also had a portacath – a device implanted under the skin to assist with treatments such as the administering of intravenous fluids, blood transfusions and medication – placed under her neck.

“I'd be nauseous from all of the medication," she recalls. "I'd throw up and the pressure of vomiting gave me a bleeding nose and a headache, so every day was just the worst day of my life.” 

organ donor, organ transplant, lung transplant

Fawn was attached to a labyrinth of tubes and had a bandage covering her 64 staples after the surgery. (PHOTO: Supplied)

Fawn was just skin and bones and weighed about 40kgs. 

“To get approved for a lung transplant, you have to be sick enough to qualify but also healthy enough to go through the procedure,” she says. 

“I was so weak they didn’t want to list me – that’s why I had to have the stomach tube so that I could gain some weight. I worked really hard to get to 50kgs because that would get me onto the list.”

She was placed on the transplant list after she reached her goal weight and waited eight months for surgery.

The double lung transplant took eight hours to complete. A month later she had an additional procedure which caused complications and she was left with two punctured lungs. Fawn then spent three months in hospital where she was treated for a lung infection.

organ donor, organ transplant, lung transplant

Fawn used a lung function machine to test her new lungs. She goes for this test every 3 months to monitor how well her lungs are performing. (PHOTO: Supplied)

When she was eventually discharged, her long road to recovery began.

She needed extensive physical therapy to help her learn how to walk again because being bedridden for so long had caused her muscles to atrophy.

“It was very frustrating because you’ve waited so long for these lungs and you think ‘yay! new life’. You picture yourself running on the beach, but it was nothing like that. It was a new journey, but it was a slow process,” she shares. 

organ donor, organ transplant, lung transplant

She takes 60 pills a day to prevent organ rejection. (PHOTO: Supplied)

It took a while for her to adjust her new body "because I was so used to my old lungs," she says.

"Before, I knew exactly what was happening in my body, I knew when I was about to get an infection, but I didn’t know these new lungs, so it was just strange.”

She also had to learn to trust her body.

“I remember laughing for the first time, I got a fright at how deep and long my laughs were because before the transplant I had an energy-saving laugh – the ‘haha', that’s funny laugh.”

organ donor, organ transplant, lung transplant

Travis and Fawn have been married since 2020. (PHOTO: Supplied)

Her life has changed dramatically since her transplant. A few years ago she didn't think she'd ever leave hospital, let alone walk down the aisle to say her I do's.

Fawn married her best friend, Travis Kruger, in 2020 and runs a digital marketing agency business alongside him.

She's also the co-founder of an non-profit organisation called TELL which educates people about organ and tissue donation in SA. 

She knows how important organ donors are.

“When they found my donor, I think I must only have had a couple of days to live," she says.

READ MOREFrom Disney darling to budding entrepreneur, Selena Gomez is on a roll

To mark the 10-year anniversary of her double lung transplant, she asked her family and friends to donate to her Lungaversary Backabuddy campaign instead of buying her gifts.

She's already raised R30 000 of the R100 000 she'd like to collect to help TELL in their continued efforts to educate the public about organ donation.

organ donor, organ transplant, lung transplant

Fawn is grateful to her donor for the life that she has now. (PHOTO: Supplied)

Fawn takes 60 tablets a day and visits specialists every three months for routine check-ups but she's finally breathing easier now.

She's incredibly grateful to her 13-year-old donor for giving her a new lease of life and has a message for anyone who finds themselves in the same situation.

“For those waiting for a transplant, don’t give up – it’s so difficult and giving up is seems so much easier but it really is worth the fight," she says. 

"For those who've had a transplant, keep fighting. A transplant isn't a cure, some days are harder than others. But life is always worth fighting for.” 

Extra sources:

Source link

Pulmonary rehabilitation is a program offered at Veterans Memorial Hospital in Waukon that teaches a person to live and breathe better with chronic lung disease. Conditions such as emphysema, chronic bronchitis, asthma, restrictive lung disease and cystic fibrosis can make doing everyday activities difficult due to shortness of breath and low activity tolerance. Participation in a pulmonary rehab program can help increase strength, manage shortness of breath, decrease anxiety and depression, and implement a consistent at-home exercise program.

Pulmonary Rehabilitation consists of closely supervised exercise sessions staffed by Amy Rolfs, RN and Diann Weymiller, RN. During these sessions heart rate, blood pressure, oxygen level, shortness of breath and exercise tolerance are monitored and assessed. Sessions also include education about breathing techniques, energy conservation, medications, oxygen use and self evaluation to help increase a person’s activity tolerance.  The pulmonary rehab staff also provide other information that helps set goals and create a plan for managing  chronic lung disease and improving quality of life.

Monica Monserud of Waterville has utilized the cardio-pulmonary program at Veterans Memorial Hospital. “I was sick for two weeks and then went to see a doctor, to find out my oxygen level was low and I was dehydrated,” explains Monserud. “I have been attending this program to work at building myself back up again.”

For more information in understanding and managing pulmonary function and improving health, call the Rehabilitation Department at Veterans Memorial Hospital at 563-568-3411.

Source link

New York, March 06, 2023 (GLOBE NEWSWIRE) -- According to The Insight Partners, “Respiratory Inhalers Market Size, Share, Growth, Trends and Global Forecast to 2028 - COVID-19 Impact and Global Analysis By Product Type [Nebulizers, Metered Dose Inhalers (MDI), and Dry Powder Inhalers], Technology (Manually Operated Inhalers and Digitally Operated Inhalers), and Disease Indication (Asthma, COPD, Pulmonary Arterial Hypertension, and Others)” the global respiratory inhalers market growth is driven by rising cases of respiratory disorders, growing adoption of generic inhalers and increasing adoption of smart inhalers technology.

Download PDF Brochure at

Global Respiratory Inhalers Market – Report Scope:

Market Size Value in USD 31.14 Billion in 2022
Market Size Value by USD 43.44 Billion by 2028
Growth rate CAGR of 5.7% from 2022 to 2028
Forecast Period 2022-2028
Base Year 2022
No. of Pages 254
No. of Tables 165
No. of Charts & Figures 77
Historical data available Yes
Segments covered Product Type, Technology, and Disease Indication

Global Respiratory Inhalers Market Analysis: Competitive Landscape and Key Developments

AstraZeneca Plc; Beximco Pharmaceuticals Ltd.; Boehringer Ingelheim International GmbH; Cipla Ltd.; GSK Plc; Koninklijke Philips NV; OMRON Corp; PARI Respiratory Equipment, Inc.; Teva Pharmaceutical Industries Ltd.; and OPKO Health, Inc. are a few of the key companies operating in the respiratory inhalers market. The market leaders focus on new product launches, expansion and diversification, and acquisition strategies, which allow them to access prevailing business opportunities.

In January 2023, FDA approved Airsupra [pressurized metered-dose inhaler (pMDI)], manufactured by AstraZeneca Plc, in the US for the as-needed treatment or prevention of bronchoconstriction. Airsupra is a first-in-class, pressurized metered-dose inhaler (pMDI), fixed-dose combination rescue medication containing albuterol, a short-acting beta2-agonist (SABA), and budesonide, an anti-inflammatory inhaled corticosteroid (ICS) in the US.

In September 2022, Beximco Pharmaceuticals launched ONRIVA TRIO BEXICAP, which is a dry inhaler capsule. ONRIVA TRIO BEXICAP is the preparation of Indacaterol (150 µg), Glycopyrronium (50 µg), and Mometasone (160 µg). It controls asthma symptoms in three ways. Indacaterol and Glycopyrronium help the muscles of lung airways to stay relaxed to prevent bronchoconstriction, while Mometasone helps to decrease inflammation. ONRIVA TRIO BEXICAP is indicated as maintenance therapy in severe persistent asthma.

In January 2021, Fluticasone Propionate and Salmeterol (‘FPSM’) Dry Powder Inhaler 100mcg, 250mcg was launched. The product contain fluticasone propionate and salmeterol (as xinafoate), which have different modes of action. Salmeterol provides symptomatic relief, while fluticasone propionate improves lung function and prevents exacerbations of the condition. Fluticasone propionate/Salmeterol can offer a more convenient regimen for patients on concurrent long-acting beta-agonist and inhaled corticosteroid therapy.

Inquiry Before Purchase:

Increasing Adoption of Smart Inhalers Technologies Provides Lucrative Opportunities for Global Respiratory Inhalers Market Growth:

Smart inhalers ensure that people suffering from asthma take their medication as prescribed by recording the timing and dosage on their smartphones. The data collected can be used by a clinician to verify that the prescribed treatment is working, personalize asthma reviews to focus on the root causes of worsening symptoms, and provide early warning systems that inform when to visit a clinic. This technology could shift from one-size-fits-all asthma screening and lead to fewer routine appointments, which could ease pressure on the National Health Service (NHS). Smart inhalers benefit adults and the geriatric population, as they struggle to take the same puffs due to uneven breathing as the muscles that support breathing and the diaphragm weaken with age, preventing air from inhaling or exhaling. Smart inhalers that are equipped with sensors can be connected to conventional inhalers and help to keep track of when the medication is taken. Being Bluetooth-enabled, they can also be remotely paired with a computer or smart device, such as a phone or tablet, to transfer data from the smart inhaler automatically. In India, the demand for smart inhalers has increased due to the rising prevalence of respiratory diseases, such as asthma and COPD, and smoking habits. According to the University of Washington's 2018 Global Burden of Disease study, COPD was India's second leading cause of death, resulting in ~958,000. In addition, according to the Tobacco Atlas, more than 625,000 children between the ages of 10 and 14 and 1 billion adults over the age of 15 use tobacco every day in India. Therefore, the above-mentioned applications of smart inhalers and their growing adoption are expected to provide growth opportunities to the respiratory inhalers market in the coming years.

Check Discount on this Report at

The US holds a significant market share of the respiratory inhalers market. Asthma and chronic obstructive pulmonary disease (COPD) are major health burdens in the US. Asthma is a chronic inflammatory disorder due to airway narrowing and obstruction. COPD is due to obstruction of airflow from the lungs, which causes chronic inflammatory lung disease. Smoking is the main cause of COPD in the US. According to the Centers for Disease Control and Prevention (CDC), in 2020, ~5.0% of adults were diagnosed with COPD, emphysema, or chronic bronchitis in the US. Approximately 25 million people were affected by asthma, and ~14.8 million had COPD in 2020. COPD was the fourth leading cause of death in the US in 2018. Furthermore, ~1 in every 10 infants born in 2020 were preterm births. Thus, the growing prevalence of chronic respiratory disorders and preterm births in the US is driving the respiratory inhalers market. In addition, according to Administration for Community Living, in 2019, the population aged 65 years and above in the US was ~54.1 million, contributing to 16% of the total population. It is expected to reach 21.6% by 2040. The older population is more susceptible to various chronic respiratory diseases. Thus, a continuous rise in the older population is expected to boost the growth of the respiratory inhalers market during the forecast period.

Global Respiratory Inhalers Market: Segmental Overview

Based on product type, the respiratory inhalers market is segmented nebulizers, metered dose inhalers (MDI), and dry powder inhalers. The dry powder inhalers segment is further bifurcated into multi-dose dry powder inhalers and single-dose dry powder inhalers. The metered dose inhalers (MDI) segment is further divided into pressured metered dose inhalers and connected metered dose inhalers. The nebulizers segment is subsegmented into compressed air nebulizers, mesh air nebulizers, and ultrasonic air nebulizers. In 2022, the dry powder inhalers segment accounted for the largest market share. However, the metered dose inhalers (MDI) segment is anticipated to register the highest CAGR during the forecast period. Based on technology, the respiratory inhalers market is bifurcated into manually operated inhalers and digitally operated inhalers. The manually operated inhalers segment held a larger share of the market in 2022 and is expected to register a higher CAGR during the forecast period. Based on disease indication, the respiratory inhalers market is segmented into asthma, COPD, pulmonary arterial hypertension, and others. The asthma segment held the largest share of the market in 2022 and is expected to grow at the highest CAGR during the forecast period.

Buy Premium Copy of Respiratory Inhalers Market Growth Report (2022-2028) at:

Browse other research published by The Insight Partners:

Global Inhalers Market Size Forecast to 2028 - COVID-19 Impact and Global Analysis By Devices (Metered Dose Inhalers, Dry Powder Inhalers, Nebulizers, Nasal Inhalers); Type (Preventive Inhalers, Reliever Inhalers, Long Acting Bronchodilators Inhalers); Application (Asthma, Chronic Obstructive Pulmonary Diseases, Others); End User (Home Care, Hospitals and Clinics, Others)

Global Smart Inhalers Market Size to 2027 - Global Analysis and Forecasts By Product (Nebulizers and Inhalers); Disorder (Chronic Obstructive Pulmonary Disease (COPD) and Asthma); End User (Home-Care Settings and Hospitals & Clinics) and Geography

Global Medical Inhaler Market Size Forecast to 2028 - COVID-19 Impact and Global Analysis By Product (Dry Powder Inhaler, Metered Dose Inhaler, Others); Application (Asthma, Chronic Obstructive Pulmonary Disorder, Others); End User (Hospitals, Clinics, Respiratory Care Center, Others) and Geography

Global Digital Dose Inhalers Market Size Forecast to 2028 - Covid-19 Impact and Global Analysis - By Product Type ( Metered Dose Inhalers, Dry Powder Inhalers ); Application ( Asthma, COPD, Cystic Fibrosis, Others ) and Geography

Global Breath Actuated Inhalers Market Size Forecast to 2028 - COVID-19 Impact and Global Analysis By Type (Single Dose, and Multi Dose); Application (Asthma, COPD, and Others), and Geography

Global Asthma Inhaler Device Market Size Forecast to 2028 - Covid-19 Impact and Global Analysis - by Type (Metered Dose inhaler, MDI with a spacer, Dry Powder inhaler, Others.); Technology (Manually operated inhaler, Digitally operated inhaler); End User (Hospitals, Clinics, Research Institutes, Others.)

Global Soft Mist Inhalers Market Size Forecast to 2028 - COVID-19 Impact and Global Analysis By Application (COPD, Asthma); End User (Hospitals, Clinics, Others) and Geography

Global Budesonide Inhalers Market Size Forecast to 2028 - Covid-19 Impact and Global Analysis - By Product Type (Inhalants, Nebulizers); Dosage (Aerosols, Dry Powder, Suspension, Spray); Distributional Channel (Hospital Pharmacies, Retail Pharmacies, Online Pharmacies) and Geography

Global Respiratory Monitoring Devices Market Size Forecast to 2028 - Covid-19 Impact and Global Analysis - By Product (Spirometer, Pulse Oximeter, Peak Flow Meter, and Capnographs), End User (Hospitals, and Home Care) and Geography

Global Respiratory Care Devices Market Size Forecast to 2028 - COVID-19 Impact and Global Analysis By Product {Therapeutic Devices [Positive Airway Pressure (PAP) Devices (CPAP Devices, APAP Devices, and BiPAP Devices), Oxygen Concentrators (Fixed Oxygen Concentrators and Portable Oxygen Concentrators), Ventilators, Inhalers (Metered Dose Inhalers and Dry Powder Inhalers), Nebulizers, Humidifiers, and Others], Monitoring Devices (Pulse Oximeters, Capnography, and Gas Analyzers), Diagnostic Devices (Spirometers, Polysomnography Devices, Peak Flow Meters, and Other Diagnostic Devices), and Consumables & Accessories (Masks, Disposable Resuscitators, Tracheostomy Tubes, Breathing Circuits, and Other Consumables & Accessories)}, Indication [Chronic Obstructive Pulmonary Diseases (COPD), Sleep Apnea, Asthma, Infectious Diseases, and Others], and End User (Hospitals, Home Care, and Ambulatory Care)

About Us:
The Insight Partners is a one stop industry research provider of actionable intelligence. We help our clients in getting solutions to their research requirements through our syndicated and consulting research services. We specialize in industries such as Semiconductor and Electronics, Aerospace and Defense, Automotive and Transportation, Biotechnology, Healthcare IT, Manufacturing and Construction, Medical Device, Technology, Media and Telecommunications, Chemicals and Materials.

Contact Us:
If you have any queries about this report or if you would like further information, please contact us:

Contact Person: Sameer Joshi
E-mail: [email protected]
Phone: +1-646-491-9876
Press Release:

Source link

NC State student with cystic fibrosis does scientific research seeking to cure ailments like hers

Published 12:10 am Sunday, March 5, 2023

SALISBURY — Grace Hodge wants to help as many people as she can since being diagnosed with cystic fibrosis when she was 3. She’s also doing everything in her power to make sure anyone who is dealing with a disease like her doesn’t become defined by their diagnosis.

“Your life is not sickness, it’s not despair. You have joy and you have light and that’s something that you need to remember,” said the Cleveland resident who is now at N.C. State University.

Cystic fibrosis is a genetic disease that causes an increased amount of mucus in the lungs and pancreas. Symptoms include malnutrition, poor growth, frequent respiratory infections, breathing problems and chronic lung disease. Normally, Grace’s doctors would have realized she had the disorder before she was 3, but North Carolina didn’t have mandatory newborn screenings at the time she was born.

Grace’s mom started to notice things were wrong as she grew. She took her to the doctor and and made them test Grace for a bacteria in her stool called pseudomonas. That’s when they found out she had it. “My mom is the one who figured it out and not any doctors,” Grace said.

She was hospitalized immediately afterwards for treatment to make up for the time before she was diagnosed. She got the necessary medical equipment and medication to help with the mucus. Growing up, her symptoms weren’t as severe, but she still had to make two-week trips to the hospital twice a year.

“Being a child and in school, you kind of stress about those things, but I would sit in my hospital room and do my schoolwork and still get my treatments,” Grace said.

Usually as people get older, cystic fibrosis gets worse, but Grace’s hospital visits decreased to the point where she hasn’t had a serious problem in several years. In 2019, genetic modulator treatment was introduced to deal with cystic fibrosis and it has done wonders for her overall health.

“My two mutations, I have a protein channel, but my protein is misfolded so it can’t get through to the right channel,” Grace said.

Genetic modulator treatment got the protein folded correctly and cut down on her symptoms significantly, “which was amazing at that time and it was something brand new that they never had much success doing that before,” she said.

Now 20 and majoring in biological sciences, she hasn’t been seriously hospitalized since 2016. She said her current doctors are “amazed at my progress.”

Still, Grace has a routine that requires her to do breathing treatments twice a day, wear a lifejacket-type machine that pulsates air to shake the mucus out of her lungs and take daily medication. By now, she’s gotten the hang of it and is feeling better than ever.

“There’s very little mucus production, I’m able to walk to class and be fine, I’m able to play sports if I chose to. There’s not many things now that hinder my day-to-day activities,” Grace said.

Originally, she had dreams of becoming a doctor and working as a pediatric pulmonologist, which is the kind of specialist she sees for CF, but when she realized there wouldn’t be a cure in the near future, she decided to start working in genetic biology.

“That’s just what I find most fascinating,” Grace said.

At N.C. State, her first year of college was during COVID, so she didn’t get hands-on experience she needed. At such a large school, she was not able to get into any of the labs for research.

Luckily, her mother works at the W.G. “Bill” Hefner VA Medical Center in Salisbury, where she learned about the VA South Central Appalachian Network for Research Development (VA SCAN-RD) program. It focuses on “limited access to research opportunities for underserved, minority and rural veterans.”

After she was accepted, she finally got do the kind of work she had been wanting to do for as long as she could remember. “That was able to give me enough boost that I felt like I needed to really know that this is what I wanted to go in to,” Grace said.

Her mentor, Dr. Miranda Orr, works at the Wake Forest University School of Medicine, where research for the VA SCAN-RD takes place. Orr is impressed with the work Grace is doing and also with her as a person.

“You would not even know she has this disease that she is dealing with every day,” Orr said. “You would never know. She is just so optimistic, so cheerful. She’s just a really remarkable young lady.”

Last summer, Grace went to Wake Forest a few times a week to be a part of Orr’s research and was able to learn basic laboratory techniques, how to measure correct amounts, the ethics involved in research, communication, collaboration and analysis of results.

Grace is happy to have someone like Orr to guide her. “She’s been the most in-depth mentor, lab technician, lab leader that I’ve ever had,” Grace said.

“It’s incredibly rewarding to provide research opportunities to very young, curious adults hoping to get them more engaged in science and think about all the different career paths,” Orr said.

Grace will be in the VA SCAN-RD again this summer. This time, she’ll have more freedom with her work. Grace wants to get into gene therapy and help cure diseases, even if it’s not CF. “I’m more interested in to being able to really conduct my own research and hopefully get a poster or a paper, my name out there somewhere,” Grace said.

She has had plenty of emotional and medical support, but doesn’t know yet what she wants to focus on after she graduates. She does have an idea. “I want to be able to go somewhere that can help fuel progress,” she said.

As her symptoms remain manageable, Grace is making the most of her potential and not letting CF shape who she is.

“I think that the most important thing that you can do when having a chronic, progressive disease is hope. … I think that it’s important to keep who you are inside and yes, have CF be a part of you, but it is not who you are,” Grace said.

Source link

China Cystic Fibrosis Therapeutics Market

China Cystic Fibrosis Therapeutics Market

Report Overview

The China Cystic Fibrosis Therapeutics market size stood at USD xx billion in 2019 and is projected to reach USD xx billion by 2028, exhibiting a CAGR of xx% during the forecast period.

The diagnosis and treatment of Cystic Fibrosis disease are an important public health issue and a challenge for medical care in China. The Incidence rate of Cystic Fibrosis disease in China is 1 person per 1,00,000. With its enormous population, increase in paediatric population (14.65 million in 2019) and economic inequalities, several mutations (1898+5G>T, c.2909G>A, 3068T>G) in cystic fibrosis disease in China faces considerable challenges in improving the standard of care for patients who are affected by cystic fibrosis disease. It is found that the median age of a patient who is affected by cystic fibrosis is 10.55 years old.

Market Drivers

China is the growing market for Cystic Fibrosis disease due to increasing paediatric population (14.65 million in 2019), increase in mutation of genes, rise in smoking rates (300 million smokers in 2019 and 180 million children are exposed to second-hand smoke at least once a day in typical week) results in increase in Prevalence rate. Advances in screening and treatment technologies will lead to increase in market growth of cystic fibrosis disease. The growing focus of companies towards product enhancement and clinical studies will foster the growth of the market.

There are some restraining factors for the growth of Cystic Fibrosis therapeutics market in China such as complex drug development process, expensive treatment options, under diagnosis, misdiagnosis and missed diagnosis.

Get Exclusive Free Sample Report @

Major Players

Some of the key players in the Cystic Fibrosis therapeutics market are Actavis Pharma Inc; Vertex Pharmaceuticals LLC; Aridis Pharmaceuticals Inc; Arcturus Therapeutics Inc; Johnson & Johnson and others.

Key players are adopting various strategies such as strategic collaboration to increase their market share and also to develop new therapy for effective treatment of the disease. For instance, Arcturus Therapeutics announces strategic collaboration with Johnson and Johnson innovation to discover and develop RNA medicines. It also received up to 3 million dollars from cystic fibrosis foundation to advance a novel LUNAR formulated mRNA CFTR therapeutic.

The report delivers the challenges in front of the China Cystic Fibrosis Therapeutics Market 2023 that allows a better understanding of the market providing a helpful comprehensive evaluation and clear-cut dynamics associated with this market. The analyst has studied the current market scenario while concentrating on the new business objectives with the lucrative opportunities that are available. This report includes changes in customer requirements, customer preferences, and the vendor landscape in the industry with key factors that are expected to influence the overall dynamics of the China Cystic Fibrosis Therapeuticss Market including the current trends, growth opportunities, restraints, and market drivers.

To Know More About COVID-19 Impact On China Cystic Fibrosis Therapeutics Market @

Market Segmentation

By Drug Type:

On the basis of the drug type, the China Cystic Fibrosis therapeutics market is segmented into CFTR modulators, mucolytics, bronchodilators and pancreatic enzyme supplements.

CFTR modulators includes Ivacaftor and Lumacaftor. Mucolytics consists of Dornase Alfa, Hypertonic saline. Bronchodilator's drug includes Albuterol and Levalbuterol. Pancreatic enzyme supplements include Lipase, Protease and Amylase.

By Surgery:

On the basis of the surgery, the China cystic fibrosis therapeutics market can be segmented into lung transplant and liver transplant. Lung transplant is used in case of severe breathing problems, life-threatening lung complications or increasing resistance to antibiotics for lung infections, lung transplantation may be an option. Liver transplant- For severe cystic fibrosis-related liver disease, such as cirrhosis, liver transplant may be an option.

By Route of administration:

Based on the route of administration, the China cystic fibrosis therapeutics market has been segmented into oral, inhaled and parenteral.

Oral route is most commonly used due to safe, simple, and convenient for administration of drugs.

Inhaled- Route of administration includes bronchodilators which may widen airways by helping the surrounding muscles relax, this could allow more air to travel through the airways, which may help other medications work more effectively.

Parenteral- In case of acute or emergency treatment of disease this route is preferred.

Major Players

Some of the key players in the Cystic Fibrosis therapeutics market are Actavis Pharma Inc; Vertex Pharmaceuticals LLC; Aridis Pharmaceuticals Inc; Arcturus Therapeutics Inc; Johnson & Johnson and others.

Key players are adopting various strategies such as strategic collaboration to increase their market share and also to develop new therapy for effective treatment of the disease. For instance, Arcturus Therapeutics announces strategic collaboration with Johnson and Johnson innovation to discover and develop RNA medicines. It also received up to 3 million dollars from cystic fibrosis foundation to advance a novel LUNAR formulated mRNA CFTR therapeutic.

The China Cystic Fibrosis Therapeutics Market report is an easy-to-understand document giving section-wise details about the global market. Starting with the brief outline of the overall market, it will put forth the all-inclusive evaluated market statistics and different parameters for the forecast period. The report covers numerous aspects of the China Cystic Fibrosis Therapeutics market divided into product kind, application, and end-use, offering the report to assist the customers in improving their ability to make precise decisions related to the business under the China Cystic Fibrosis Therapeutics Market.

International Market Players will use the correct market facts and figures and applied math studies provided within the report back to perceive this and future growth of the worldwide Electrophoretic China Cystic Fibrosis Therapeutics market. Each section of the research study is specially prepared to explore key aspects of the global China Cystic Fibrosis Therapeutics Market. Buyers of the report will have access to accurate PESTLE, SWOT, and other types of analysis on the global China Cystic Fibrosis Therapeutics market. Moreover, it offers highly accurate estimations on the CAGR, market share, and market size of key regions and countries.

This post-pandemic business planning research will aid clients to:
• Adjust their strategic planning to move ahead once business stability kicks in.
• Build resilience by making effective resource and investment choices for individual business units, products, and service lines.
• Conceptualize scenario-based planning to mitigate future crisis situations.

Instant Buy This Report and Get Up To 40% Discount [Use Corporate Email ID]:

Get full copy of 225+ pages research report (Inclusion of updated research on COVID-19) on United States Region at $1500 and, Europe region at $2000. Get in touch with our sales team, who will guarantee you a report that suits your needs.

Our qualified team of researchers, analysts, and consultants use in-depth qualitative research, quantitative research, and the latest recognized research techniques to offer an unrivaled level of detail and value to your research activities. Our market and competitive intelligence can be utilized by teams across multiple departments, including sales and business development, marketing, to:

• Access the latest information on potential competitors and customers through a comprehensive database
• Analyse the business strategies and collaborations of multiple companies within a specific market
• Identify new markets and regions for future expansion
• Compare financial trends between competitor companies
• Get to know about mergers and acquisitions
• Explore the strengths and weaknesses of companies cross-industry
• Improve your business modeling

Strategic Points Covered in Table of Content of Global China Cystic Fibrosis Therapeutics Market:

Chapter 1: Introduction, market driving force product Objective of Study and Research Scope the China Cystic Fibrosis Therapeutics market
Chapter 2: Exclusive Summary - the basic information of the China Cystic Fibrosis Therapeutics Market.
Chapter 3: Displaying the Market Dynamics- Drivers, Trends and Challenges & Opportunities of the China Cystic Fibrosis Therapeutics
Chapter 4: Presenting the China Cystic Fibrosis Therapeutics Market Factor Analysis, Porters Five Forces, Supply/Value Chain, PESTEL analysis, Market Entropy, Patent/Trademark Analysis.
Chapter 5: Displaying the by Type, End User and Region/Country
Chapter 6: Evaluating the leading manufacturers of the China Cystic Fibrosis Therapeutics market which consists of its Competitive Landscape, Peer Group Analysis, BCG Matrix & Company Profile
Chapter 7: To evaluate the market by segments, by countries and by Manufacturers/Company with revenue share and sales by key countries in these various regions
Chapter 8 & 9: Displaying the Appendix, Methodology and Data Source

(If you have any special requirements, please let us know and we will offer you the report as you want.)

Inquire Before Purchasing The Complete Report To Grow Your Business:

Contact Us:
Allan Carter
Andheri, Maharashtra, 400102
USA/Canada(Toll Free): 1800-601-6071
Direct Line: +91 83560 50278
Mail: [email protected]

About Us:
We are leaders in market analytics, business research, and consulting services for Fortune 500 companies, start-ups, financial & government institutions. Since we understand the criticality of data and insights, we have associated with the top publishers and research firms all specialized in specific domains, ensuring you will receive the most reliable and up to date research data available. To be at our client's disposal whenever they need help on market research and consulting services. We also aim to be their business partners when it comes to making critical business decisions around new market entry, M&A, competitive Intelligence and strategy.

This release was published on openPR.

Source link

Despite another round of winter weather, local firefighter braved the elements to travel to Vancouver for a good cause.

On Sunday, Feb. 26, Four members of the Harrison Hot Springs Fire Department entered the Sheraton Vancouver Wall Centre annual for the annual Climb The Wall event to support the B.C. Lung Foundation and people living with asthma and other respiratory conditions.

Dressed in full bunker gear – which can weigh at least 50 pounds – the firefighters climbed all 48 storeys of the Sheraton Wall Centre.

Harrison firefighters raised $1,145 for the B.C. Lung Foundation; their contribution is part of a grand total of $136,356 raised this year. Donations handily surpassed the $125,000 goal.

Agassiz and Harrison firefighters are often represented at Climb the Wall; hundreds of firefighters and civilian climbers congregate in Vancouver every year to support the cause.

One in five British Columbians lives with lung or breathing conditions, including asthma, chronic obstructive pulmonary disease (or COPD, sleep apnea, lung cancer, pulmonary fibrosis and cystic fibrosis.

To learn more about the B.C. Lung Association and how you can help, visit

[email protected]

Like us on Facebook and follow us on Twitter.

Harrison Hot Springs

Source link

Dublin, March 03, 2023 (GLOBE NEWSWIRE) -- The "Cystic Fibrosis Therapeutics Market, Size, Global Forecast 2023-2028, Industry Trends, Growth, Impact of Inflation, Company Analysis" report has been added to's offering.

The Global Cystic Fibrosis industry was valued at US$ 10.86 Billion in 2022 and is expected to reach US$ 24.35 Billion by 2028, at a CAGR of 14.4%

Cystic Fibrosis is an ongoing genetic disease that affects the lungs and other body systems (Pancreas, Liver, and Kidney) and for which there is currently no cure. It mainly affects the digestive and respiratory systems in children and young adults. About half of the population with cystic fibrosis will live past 40. It can cause problems with digestion and breathing from childhood age.

Over a decade, the lungs become increasingly damaged and may eventually stop working correctly. The primary target organs in cystic fibrosis are the sweat glands, the lungs, and the gastrointestinal tract, particularly the pancreas.

Although clinically the least serious problem, increased sodium and chloride concentration in sweat is the undisputed hallmark of cystic fibrosis. The main symptoms of cystic fibrosis include chest infections, difficulty putting on weight, wet-sounding coughs, and others. Physical therapy is used to treat cystic fibrosis, which helps reduce mucus from the lungs, Provide complete nutrition, etc.

The outlook for cystic fibrosis has improved considerably in recent five years due to advancements in RD of treatment, although most people with cystic fibrosis will have shorter-than-average life assurance. According to Cystic Fibrosis Patient Registry, more than 30,000 people are currently suffering from this condition in the U.S., while more than 70,000 people are suffering from Cystic Fibrosis across the globe. In addition to this, more than approximately 1000 new cases of the disease are diagnosed every year.

Rising spending on R&D research and other technological advancements in these therapeutic areas will open a new source of growth for industry participants. However, the higher cost of therapy, and several adverse effects of currently available drugs, such as liver problems, upper respiratory tract infection, chest pain, and increased blood pressure, among others, will restrain the industry growth.

By Route of Administration: Inhale market will capture maximum share in the forecast Period

Based on the Route of Administration, The Global Cystic Fibrosis market has been divided into two types oral and inhaled. The Inhale holds significant share due to their use leading to high drug levels within the airways, with lean systemic effects, and High-quality devices providing safe and convenient antibiotic and mucolytic therapy for individuals with Cystic Fibrosis dominate the market.

Medication Treatment Method holds Largest Market

Based on Treatment, Medication captured the largest share during the forecast period due to antibiotics to prevent and treat chest infections, to make the mucus easier to cough up, the lungs thinner, and medicines to reduce inflammation and widen the airways.

In addition, other factors such as rising demand and awareness about advance help stimulate the industry's expansion and significantly affect market share. The market has been categorized into Medication, Devices, and Other Treatments. Devices also hold the significant market revenue as the most commonly used pieces of equipment for CF treatments are compressors, nebulizers, and airway clearance devices. These are readily available in the market and convenient for patients.

By Test Type: Pulmonary Function Test Type holds the Significant Market

On the Test Type segment, the Global Cystic Fibrosis Therapeutics Market has been differentiated into Pulmonary Function, Sweat, IRT, Fecal, and Genetic.

The Pulmonary Function Test holds the most significant revenue in 2022 due to the tests measuring lung volume, capacity, rates of flow, and gas exchange. This information can help healthcare providers diagnose and decide the treatment of certain lung disorders has significantly dominated the segment.

By Distribution Channels: Hospitals holds the Maximum Revenue

By Distribution Channels, Hospitals hold the maximum revenue due to the growing demand for the disease and the need for the right diagnosis and follow-up treatments under medical supervision.

This leads to an increase in patient hospital visits, moving the growth of the hospital segment. Moreover, earnings generated by hospital pharmacies are proportionately high because infected people commonly visit nearby hospitals for doctor's prescription medicines and appointments. Therefore, the market is segmented into Hospitals, Retail Pharmacies, and Others.

CFTR Modulators Drug Class will gain the maximum revenue in upcoming years

Subjected to drug class, the Global Cystic Fibrosis industry has been grouped into Pancreatic Enzyme Supplements Drug, Mucolytic Drugs, Bronchodilators Drug, and CFTR Modulators Drug.

The CFTR Modulators Drug holds the maximum revenue because CFTR modulator drugs are novel-specialized therapies that enhance the functional expression of CFTR mutants and have been approved for clinical use for individuals with specific CF genotypes. Highly effective CFTR modulator drugs are expected to modify the disease course for most individuals with CF profoundly.

In addition, advanced experimental approaches have been established to accelerate the development of novel modulators, effectively boosting the Cystic Fibrosis Therapeutics Market.

North America will capture the maximum market in forecast period

By Region, the Global Cystic Fibrosis Market has been divided into North America, Latin America, Europe, Asia Pacific, and Others. However, North America dominated the market share due to demand from the increasing occurrence of cystic fibrosis and the accessibility of several treatment options in the Region.

Moreover, rising government initiative such as increasing funding for innovations and R&D projects on cystic fibrosis drug drives the industry revenue. For instance, the North American Cystic Fibrosis Conference (NACFC gives an educational forum for cystic fibrosis specialists to share developments in R&D related to cystic fibrosis therapeutics.

In addition, other factors, such as the presence of foremost market leaders, reimbursements, and well-established healthcare infrastructure, will propel the North American market demand over the forecast timeframe.

Key Metrics

Report Attribute Details
No. of Pages 160
Forecast Period 2022 - 2028
Estimated Market Value (USD) in 2022 $10.86 Billion
Forecasted Market Value (USD) by 2028 $24.35 Billion
Compound Annual Growth Rate 14.4%
Regions Covered Global

Company Profiles: Overviews, Recent Developments, Revenues

  • Vertex Pharmaceuticals
  • Abbvie Inc.
  • Novartis Ag
  • Gilead Sciences
  • Viatris INC
  • Pfizer
  • Astrazeneca

Route of Administration - Cystic Fibrosis Therapeutics Market Analysis have been Covered from 2 Viewpoints

Treatment - Cystic Fibrosis Therapeutics Market Analysis have been Covered from 3 Viewpoints

  • Medication
  • Devices
  • Other Treatment

Test Type - Cystic Fibrosis Therapeutics Market Analysis have been Covered from 5 Viewpoints

  • Plumonary Function
  • Sweat Calories
  • IRT Test
  • Faceal Tests
  • Genetic Tests

Distribution - Cystic Fibrosis Therapeutics Market Analysis have been Covered from 3 Viewpoints

  • Hospital
  • Retail Pharmacies
  • Others

Drug Class - Cystic Fibrosis Therapeutics Market Analysis have been Covered from 4 Viewpoints

  • Pancreatic Enzyme Supplements
  • Mucolytics
  • Bronchodilators
  • CFTR Modulators

For more information about this report visit

About is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.


Source link

Spirometer Market size, share

Spirometer Market size, share

"Global Spirometer Market Expected to Reach $1.47 Billion by 2027, Driven by Increasing Prevalence of Respiratory Diseases."

PORTLAND, OREGON, UNITED STATES, February 28, 2023 / -- ???????????????????????????????????? ???????? ???????????? ????????????????????????????????, ???????????? ???????????????????????? ???????????????????????????????????????? ???????????????????????? ???????????????? ???????????? ???????????????????????????????????? ???????? ???????? $1,079.51 ???????????????????????????? ???????? 2019 ???????????? ???????? ???????????????????????????????? ???????? ???????????????? ???????? $1,471.59 ???????????????????????????? ???????? 2027, ???????? ???? ???????????????????????????????? ???????????????????????? ???????????????????????? ???????????????? (????????????????) ???????? 3.5% ???????????????? 2020 ???????? 2027. A spirometer is a medical device used to measure lung capacity and function. It is used to diagnose and monitor respiratory conditions such as asthma, chronic obstructive pulmonary disease (COPD), and cystic fibrosis.

The basic design of a spirometer involves a tube or chamber that is filled with air and a mechanism for measuring the flow and volume of the air as it is inhaled and exhaled by the patient. The patient is instructed to breathe in and out through a mouthpiece attached to the spirometer, and the device records various measures of lung function, including the amount of air that can be forcefully exhaled in one second (forced expiratory volume, or FEV1), the total amount of air that can be exhaled after a deep breath (forced vital capacity, or FVC), and the maximum volume of air that can be inhaled in one breath (inspiratory capacity).

???????????????????????????????? ???????????? ???????????????????????????????? ???????? :

Spirometry is a non-invasive and relatively simple test that can provide important information about lung function. It can help doctors diagnose respiratory conditions, determine the severity of these conditions, and monitor the effectiveness of treatment over time. Technological advances for new devices, regulatory approvals, and product launches are further promoting market growth. The prevalence of air pollution, climate changes, and dust are also fueling the spirometer market growth. Respiratory diseases are witnessing exponential rise across the world. In 2017, according to the WHO, respiratory diseases were considered to be the leading cause of death and disability in the world. Nearly 65 million people suffer from chronic obstructive pulmonary disease (COPD), and 3 million are expected to die from it each year, making it the third leading cause of death across the world.

???????????? ???????????????????????? ???????????????????????????????? ???? ???????????????????????????????????????????????????? ???????????????????????????????? ???????? ???????????? ???????????????????????????? ???????????????????????????????????? ???????????????????????????????????? ???????? ???????????? ???????????????????????? ???????????????????????????????????????? ???????????????????????? ????????????

2. Hill-Rom
3. Midmark Corp.
4. Vitalograph
5. COSMED srl
6. MGC Diagnostics
7. Smiths Medical
8. Vyaire Medical
9. Teleflex

 ???????????????????????????????????????? ???????????????????????? ???????????????????????? ????????????????????????????????????????

By Type:
• Hand-Held: A portable spirometer that is small and lightweight, making it convenient for use in clinics, hospitals, and at home.
• Table-Top: A larger spirometer that is typically used in hospitals and clinics for more advanced lung function testing.

By Technology:
• Volume Measurement: A spirometer that measures the volume of air that is inhaled and exhaled during a breathing test.
• Flow Measurement: A spirometer that measures the flow of air during a breathing test.

By Application:
• Asthma: A condition where the airways in the lungs become inflamed, leading to difficulty breathing.
• COPD: A group of lung diseases that make it hard to breathe, including chronic bronchitis and emphysema.
• Others: Other respiratory conditions that can be diagnosed and monitored using a spirometer, such as cystic fibrosis and pulmonary fibrosis.

By End User:
• Hospitals and Clinics: Healthcare facilities that provide spirometry testing as part of respiratory function testing for patients.
• Home Healthcare: Spirometry testing that is done at home, often with the use of a handheld spirometer.
• Others: Other settings where spirometry testing may be done, such as research labs or occupational health clinics.

???????????????????????????? ???????????????????????? ???????????????????????????????? :

???????? ????????????????????????

North America:

United States, Canada, and Mexico are included in this region.
North America is expected to have a significant share of the spirometer market due to factors such as a high prevalence of respiratory diseases, growing awareness about the importance of early diagnosis and treatment, and advanced healthcare infrastructure.

Germany, France, the United Kingdom, and the rest of Europe are included in this region.
Europe is also expected to have a significant share of the spirometer market due to factors such as a high burden of respiratory diseases, favorable reimbursement policies, and the presence of major market players.

Japan, China, Australia, India, and the rest of Asia-Pacific are included in this region.
Asia-Pacific is expected to have the highest growth rate in the spirometer market due to factors such as a large patient pool, increasing healthcare spending, and growing awareness about respiratory health.

Brazil, Saudi Arabia, South Africa, and the rest of LAMEA (Latin America, Middle East, and Africa) are included in this region.
LAMEA is expected to have a moderate growth rate in the spirometer market due to factors such as a high burden of respiratory diseases and increasing healthcare spending.

???????????????????????????????????????? ???????????????????? ?????????????????????????????????????

1. What is a spirometer, and how does it work?
2. What are some of the key factors driving the growth of the spirometer market?
3. What are the different types of spirometers available, and how do they differ?
4. What are the different technologies used in spirometry, and how do they work?
5. What are some of the key applications for spirometry testing?
6. What are some of the major end users of spirometry devices, and how do their needs differ?
7. Which regions are expected to have the highest growth rates in the spirometer market, and why?
8. Who are some of the key players in the spirometer market, and what are their market shares?
9. How has the COVID-19 pandemic impacted the spirometer market, and what are the implications for future growth?
10. What are some of the challenges facing the spirometer market, and how can they be addressed?

???????????? ???????????????????????????? ???????????????? ???????? ???????????????????????????????????????? ???????????????????????? ???????????????????????? ????????: [Yesterday 10:27 PM] Nilesh Musale

David Correa
Allied Analytics LLP
+ +1 503-894-6022
email us here

Source link